{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,3,25]],"date-time":"2026-03-25T08:21:17Z","timestamp":1774426877779,"version":"3.50.1"},"reference-count":346,"publisher":"Wiley","issue":"8","content-domain":{"domain":["wiley.com","cochranelibrary.com"],"crossmark-restriction":true},"short-container-title":[],"DOI":"10.1002\/14651858.cd014201","type":"journal-article","created":{"date-parts":[[2021,8,18]],"date-time":"2021-08-18T12:50:39Z","timestamp":1629291039000},"update-policy":"https:\/\/doi.org\/10.1002\/crossmark_policy","source":"Crossref","is-referenced-by-count":6,"title":["Clotting factor concentrates for preventing bleeding and bleeding-related complications in previously treated individuals with haemophilia A or B"],"prefix":"10.1002","volume":"2021","author":[{"given":"Omotola O","family":"Olasupo","sequence":"additional","affiliation":[{"name":"Department of Health Research Methods, Evidence and Impact (HEI); McMaster University; Hamilton Canada"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Megan S","family":"Lowe","sequence":"additional","affiliation":[{"name":"Department of Health Sciences; McMaster University; Hamilton Canada"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ashma","family":"Krishan","sequence":"additional","affiliation":[{"name":"School of Health Sciences, Division of Population Health, Health Services Research & Primary Care; University of Manchester; Manchester UK"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Peter","family":"Collins","sequence":"additional","affiliation":[{"name":"Arthur Bloom Haemophilia Centre, Heath Park; School of Medicine, Cardiff University; Cardiff UK"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Alfonso","family":"Iorio","sequence":"additional","affiliation":[{"name":"Department of Health Research Methods, Evidence and Impact (HEI); McMaster University; Hamilton Canada"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Davide","family":"Matino","sequence":"additional","affiliation":[{"name":"Department of Internal Medicine; McMaster University; Hamilton Canada"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"311","published-online":{"date-parts":[[2021,8,18]]},"reference":[{"key":"10.1002\/14651858.CD014201-BIB0001|cit1","first-page":"21","article-title":"Long-term efficacy of recombinant factor VIII Fc fusion protein (rFVIIIFc) prophylaxis in adults, adolescents, and children with severe hemophilia A: longitudinal analysis of A-LONG and ASPIRE studies","volume":"23 Suppl 3","author":"Konkle","year":"2017","journal-title":"Haemophilia"},{"key":"10.1002\/14651858.CD014201-BIB0002|cit2","first-page":"94","article-title":"Analysis of clinical target joint bleeding on prophylactic regimens with recombinant Factor VIII Fc fusion protein in patients with severe hemophilia A","volume":"20 Suppl 3","author":"Kulkarni","year":"2014","journal-title":"Haemophilia"},{"issue":"3","key":"10.1002\/14651858.CD014201-BIB0003|cit3","doi-asserted-by":"crossref","first-page":"317","DOI":"10.1182\/blood-2013-10-529974","article-title":"Phase 3 study of recombinant factor VIII Fc fusion protein in severe hemophilia A","volume":"123","author":"Mahlangu","year":"2014","journal-title":"Blood"},{"issue":"1","key":"10.1002\/14651858.CD014201-BIB0004|cit4","first-page":"1","article-title":"Long-acting recombinant factor VIII Fc fusion protein (rFVIIIFc) for perioperative haemostatic management in severe haemophilia A","volume":"116","author":"Mahlangu","year":"2016","journal-title":"Thrombosis and Haemostasis"},{"issue":"11","key":"10.1002\/14651858.CD014201-BIB0005|cit5","doi-asserted-by":"crossref","first-page":"1788","DOI":"10.1111\/jth.12723","article-title":"Recombinant factor VIII Fc fusion protein: extended-interval dosing maintains low bleeding rates and correlates with von Willebrand factor levels","volume":"12","author":"Shapiro","year":"2014","journal-title":"Journal of thrombosis and haemostasis : JTH"},{"issue":"6","key":"10.1002\/14651858.CD014201-BIB0006|cit6","doi-asserted-by":"crossref","first-page":"866","DOI":"10.1111\/hae.12987","article-title":"Changes in health-related quality of life with treatment of longer-acting clotting factors: results in the A-LONG and B-LONG clinical studies","volume":"22","author":"Wyrwich","year":"2016","journal-title":"Haemophilia"},{"issue":"1","key":"10.1002\/14651858.CD014201-BIB0007|cit7","doi-asserted-by":"crossref","first-page":"81","DOI":"10.1111\/j.1365-2141.1976.tb00973.x","article-title":"Prophylaxis in haemophilia: a double-blind controlled trial","volume":"33","author":"Aronstam","year":"1976","journal-title":"British Journal of Haematology"},{"issue":"1","key":"10.1002\/14651858.CD014201-BIB0008|cit8","doi-asserted-by":"crossref","first-page":"65","DOI":"10.1136\/jcp.30.1.65","article-title":"Twice weekly prophylactic therapy in haemophilia A","volume":"30","author":"Aronstam","year":"1977","journal-title":"Journal of Clinical Pathology"},{"key":"10.1002\/14651858.CD014201-BIB0009|cit9","first-page":"78","article-title":"Bleed occurrence after Bay 81-8973 injection and characteristics of patients who respond to prophylaxis: analyses from Leopold I and II","volume":"22 Suppl 2","author":"Church","year":"2016","journal-title":"Haemophilia"},{"issue":"3","key":"10.1002\/14651858.CD014201-BIB0010|cit10","doi-asserted-by":"crossref","first-page":"280","DOI":"10.1007\/s12185-016-2133-9","article-title":"Analysis of the Japanese subgroup in LEOPOLD II: a phase 2\/3 study of BAY 81-8973, a new recombinant factor VIII product","volume":"105","author":"Fujii","year":"2017","journal-title":"International Journal of Hematology"},{"issue":"4","key":"10.1002\/14651858.CD014201-BIB0011|cit11","doi-asserted-by":"crossref","first-page":"528","DOI":"10.1111\/hae.13192","article-title":"Population pharmacokinetic characterization of BAY 81-8973, a full-length recombinant factor VIII: lessons learned - importance of including samples with factor VIII levels below the quantitation limit","volume":"23","author":"Garmann","year":"2017","journal-title":"Haemophilia"},{"key":"10.1002\/14651858.CD014201-BIB0012|cit12","first-page":"25","article-title":"Study design of 2 randomized, crossover, open-label trials to evaluate the pharmacokinetics, efficacy, and safety of plasma protein-free recombinant factor VIII formulated with sucrose (BAY 81-8973)","volume":"18 Suppl 3","author":"Kavakli","year":"2012","journal-title":"Haemophilia"},{"key":"10.1002\/14651858.CD014201-BIB0013|cit13","first-page":"94","article-title":"Superiority of prophylaxis versus on-demand therapy with plasma protein-free recombinant FVIII formulated with sucrose (BAY 81-8973): LEOPOLD II study results","volume":"20 Suppl 3","author":"Kavakli","year":"2014","journal-title":"Haemophilia"},{"key":"10.1002\/14651858.CD014201-BIB0014|cit14","doi-asserted-by":"crossref","first-page":"360","DOI":"10.1111\/jth.12828","article-title":"Prophylaxis vs. on-demand treatment with BAY 81-8973, a full-length plasma protein-free recombinant factor VIII product: results from a randomized trial (LEOPOLD II)","volume":"13","author":"Kavakli","year":"2015","journal-title":"Journal of Thrombosis and Haemostasis"},{"key":"10.1002\/14651858.CD014201-BIB0015|cit15","first-page":"96","article-title":"Leopold trial results: correlation of von willebrand factor antigen level with bay 81-8973 pharmacokinetic parameters of patients with severe hemophilia A","volume":"13","author":"Lalezari","year":"2015","journal-title":"Journal of Thrombosis and Haemostasis"},{"key":"10.1002\/14651858.CD014201-BIB0016|cit16","first-page":"858","article-title":"Prophylactic efficacy of twice-weekly vs. 3-times-weekly bay 81-8973 in severe hemophilia A: results of the Leopold I and II clinical trials","volume":"13 Suppl 2","author":"Mahlangu","year":"2015","journal-title":"Journal of Thrombosis and Haemostasis"},{"issue":"3","key":"10.1002\/14651858.CD014201-BIB0017|cit17","doi-asserted-by":"crossref","first-page":"349","DOI":"10.1111\/hae.12839","article-title":"Safety and efficacy of BAY 81-8973 for surgery in previously treated patients with haemophilia A: results of the LEOPOLD clinical trial programme","volume":"22","author":"Oldenburg","year":"2016","journal-title":"Haemophilia"},{"key":"10.1002\/14651858.CD014201-BIB0018|cit18","first-page":"31","article-title":"Bay 81-8973 demonstrates comparable efficacy during prophylaxis irrespective of the assay determining potency","volume":"21","author":"Saxena","year":"2015","journal-title":"Haemophilia"},{"issue":"6","key":"10.1002\/14651858.CD014201-BIB0019|cit19","doi-asserted-by":"crossref","first-page":"766","DOI":"10.1111\/hae.12691","article-title":"Pharmacokinetic properties of BAY 81-8973, a full-length recombinant factor VIII","volume":"21","author":"Shah","year":"2015","journal-title":"Haemophilia"},{"issue":"3","key":"10.1002\/14651858.CD014201-BIB0020|cit20","doi-asserted-by":"crossref","first-page":"e153","DOI":"10.1111\/hae.13751","article-title":"Efficacy and safety of prophylaxis with BAY 81-8973 in Chinese patients with severe haemophilia A enrolled in the LEOPOLD II trial","volume":"25","author":"Yang","year":"2019","journal-title":"Haemophilia"},{"key":"10.1002\/14651858.CD014201-BIB0021|cit21","doi-asserted-by":"crossref","first-page":"2","DOI":"10.1111\/j.1365-2516.2009.02155.x","article-title":"Longer-acting factor VIII to overcome limitations in haemophilia management: The PEGylated liposomes formulation issue","volume":"16 Suppl 1","author":"Di Minno","year":"2010","journal-title":"Haemophilia"},{"issue":"3","key":"10.1002\/14651858.CD014201-BIB0022|cit22","doi-asserted-by":"crossref","first-page":"354","DOI":"10.1111\/hae.12306","article-title":"Patient characteristics that influence efficacy of prophylaxis with rFVIII-FS three times per week: a subgroup analysis of the LIPLONG study","volume":"20","author":"Lalezari","year":"2014","journal-title":"Haemophilia"},{"key":"10.1002\/14651858.CD014201-BIB0023|cit23","first-page":"373","article-title":"Subgroup analyses of annualized number of bleeds with three-times-per-week prophylaxis with rFVIII-FS","volume":"9 Suppl 2","author":"Lalezari","year":"2011","journal-title":"Journal of thrombosis and haemostasis : JTH"},{"issue":"1","key":"10.1002\/14651858.CD014201-BIB0024|cit24","doi-asserted-by":"crossref","first-page":"e15","DOI":"10.1111\/hae.12294","article-title":"Correlation between endogenous VWF: ag and PK parameters and bleeding frequency in severe haemophilia A subjects during three-times-weekly prophylaxis with rFVIII-FS","volume":"20","author":"Lalezari","year":"2014","journal-title":"Haemophilia"},{"key":"10.1002\/14651858.CD014201-BIB0025|cit25","first-page":"25","article-title":"Pharmacokinetic results and correlations with intrinsic von Willebrand factor levels form a randomized, double-blind study of prophylaxis with once-weekly BAY 79-4980 vs. 3-times-weekly sucrose-formulated recombinant factor VIII","volume":"18 Suppl 3","author":"Martinowitz","year":"2012","journal-title":"Haemophilia"},{"key":"10.1002\/14651858.CD014201-BIB0026|cit26","first-page":"726","article-title":"Efficacy and safety of prophylaxis with once-weekly bay 79-4980 vs. three-times-weekly rFVIII-FS: a randomized, active-controlled, double-blind study","volume":"9 Suppl 2","author":"Powell","year":"2011","journal-title":"Journal of thrombosis and haemostasis : JTH"},{"key":"10.1002\/14651858.CD014201-BIB0027|cit27","first-page":"913","article-title":"Efficacy and safety of prophylaxis with once-weekly BAY 79-4980 compared with thrice-weekly rFVIII-FS in haemophilia A patients: a randomised, active-controlled, double-blind study","volume":"108","author":"Powell","year":"2012","journal-title":"Blood Coagulation, Fibrinolysis and Cellular Haemostasis"},{"key":"10.1002\/14651858.CD014201-BIB0028|cit28","first-page":"25","article-title":"Experience with electronic patient diaries in a randomized, double-blind study of prophylaxis with once-weekly BAY 79-4980 vs. 3-times-weekly sucrose-formulated recombinant factor VIII","volume":"18 Suppl 3","author":"Schafer","year":"2012","journal-title":"Haemophilia"},{"issue":"1","key":"10.1002\/14651858.CD014201-BIB0029|cit29","doi-asserted-by":"crossref","first-page":"41","DOI":"10.1111\/j.1600-0609.1976.tb01115.x","article-title":"Evaluation of prophylactic replacement therapy in haemophilia B","volume":"16","author":"Morfini","year":"1976","journal-title":"Scandinavian Journal of Haematology"},{"key":"10.1002\/14651858.CD014201-BIB0030|cit30","first-page":"455","article-title":"Efficacy and target joint resolution with pharmacokinetic-guided rurioctocog alfa pegol prophylaxis targeting two factor VIII trough levels in patients with severe hemophilia A: post-hoc analysis of the phase 3 propel trial","volume":"4 Suppl 1","author":"Collins","year":"2020","journal-title":"Research and Practice in Thrombosis and Haemostasis"},{"issue":"Suppl 1","key":"10.1002\/14651858.CD014201-BIB0031|cit31","first-page":"453","article-title":"Personalizing prophylaxis with rurioctocog alfa pegol in previously treated patients with severe hemophilia A: outcomes from the phase 3B continuation and phase 3 propel studies","volume":"4","author":"Escuriola-Ettingshausen","year":"2020","journal-title":"Research and Practice in Thrombosis and Haemostasis"},{"issue":"22","key":"10.1002\/14651858.CD014201-BIB0032|cit32","doi-asserted-by":"crossref","first-page":"2594","DOI":"10.1182\/blood.V128.22.2594.2594","article-title":"Immunogenicity of BAX 855 in previously treated patients with congenital severe hemophilia A","volume":"128","author":"Horling","year":"2016","journal-title":"Blood"},{"key":"10.1002\/14651858.CD014201-BIB0033|cit33","first-page":"106","article-title":"PK-guided rurioctocog alfa pegol prophylaxis in patients with severe hemophilia A targeting two FVIII trough levels: results from the phase 3 propel study","volume":"3","author":"Klamroth","year":"2019","journal-title":"Research and practice in thrombosis and haemostasis"},{"key":"10.1002\/14651858.CD014201-BIB0034|cit34","first-page":"162","article-title":"Results from a phase 3, randomized, multicenter study of rurioctocog alfa pegol PK-guided prophylaxis targeting 2 FVIII trough levels in patients with severe hemophilia A (propel study)","volume":"25","author":"Klamroth","year":"2019","journal-title":"Haemophilia"},{"issue":"13","key":"10.1002\/14651858.CD014201-BIB0035|cit35","doi-asserted-by":"publisher","first-page":"1818","DOI":"10.1182\/blood.2020005673","article-title":"Rurioctocog alfa pegol PK-guided prophylaxis in hemophilia A: results from the phase 3 PROPEL study","volume":"137","author":"Klamroth","year":"2021","journal-title":"Blood"},{"key":"10.1002\/14651858.CD014201-BIB0036|cit36","unstructured":"BAX 855 pk-guided dosing clinicaltrials.gov\/show\/nct02585960"},{"key":"10.1002\/14651858.CD014201-BIB0037|cit37","first-page":"57","article-title":"Results from a phase 3, randomized, multicenter study of Rurioctocog Alfa Pegol PK-guided prophylaxis targeting two FVIII trough levels in patients with severe hemophilia A (PROPEL Study)","volume":"25","author":"Radulescu","year":"2019","journal-title":"Haemophilia"},{"issue":"S1","key":"10.1002\/14651858.CD014201-BIB0038|cit38","first-page":"S1","article-title":"Results from a phase 3, randomized, multicenter study of rurioctocog alfa pegol PKGuided prophylaxis targeting 2 FVIII trough levels in patients with severe hemophilia A (Propel Study)","volume":"39","author":"Robert","year":"2019","journal-title":"Hamostaseologie"},{"key":"10.1002\/14651858.CD014201-BIB0039|cit39","first-page":"25","article-title":"Rurioctocog alfa pegol PK-guided prophylaxis targeting two FVIII trough levels in severe hemophilia a patients (PROPEL phase 3 study): impact of patient FVIII half-life on consumption and efficacy outcomes","volume":"26","author":"Windyga","year":"2020","journal-title":"Haemophilia"},{"key":"10.1002\/14651858.CD014201-BIB0040|cit40","unstructured":"Trial to evaluate the effect of two treatment regimens for adults with severe hemophilia A www.who.int\/trialsearch\/Trial2.aspx?TrialID=EUCTR2008-000985-21-BG"},{"key":"10.1002\/14651858.CD014201-BIB0041|cit41","first-page":"244","article-title":"Spinart 3-year analyses: patient- and joint-level changes in colorado adult joint assessment scale and magnetic resonance imaging scores with Bayer's sucrose-formulated recombinant factor VIII in adolescents and adults","volume":"13 Suppl 2","author":"Funk","year":"2015","journal-title":"Journal of thrombosis and haemostasis : JTH"},{"key":"10.1002\/14651858.CD014201-BIB0042|cit42","first-page":"63","article-title":"3-year joint outcomes in the SPINART trial: results using the Colorado adult joint assessment scale","volume":"20 Suppl 3","author":"Hong","year":"2014","journal-title":"Haemophilia"},{"key":"10.1002\/14651858.CD014201-BIB0043|cit43","first-page":"63","article-title":"Joint outcome evaluation by magnetic resonance imaging: results at the 3-year evaluation in the SPINART study","volume":"20 Suppl 3","author":"Hong","year":"2014","journal-title":"Haemophilia"},{"issue":"6","key":"10.1002\/14651858.CD014201-BIB0044|cit44","doi-asserted-by":"crossref","first-page":"e519","DOI":"10.1111\/hae.13022","article-title":"SPINART study: validation of the extended magnetic resonance imaging scale for evaluation of joint status in adult patients with severe haemophilia A using baseline data","volume":"22","author":"Hong","year":"2016","journal-title":"Haemophilia"},{"issue":"5","key":"10.1002\/14651858.CD014201-BIB0045|cit45","first-page":"830","article-title":"Randomized, controlled, parallel-group trial of secondary prophylaxis vs on-demand treatment with sucrose-formulated recombinant factor VIII in adults with severe hemophilia A","volume":"18","author":"Kempton","year":"2012","journal-title":"Haemophilia"},{"key":"10.1002\/14651858.CD014201-BIB0046|cit46","first-page":"25","article-title":"Regional differences in baseline patient-reported outcomes in a randomized, controlled, prospective trial of secondary prophylaxis VS on-demand treatment in patients with severe hemophilia A","volume":"18 Suppl 3","author":"Kempton","year":"2012","journal-title":"Haemophilia"},{"key":"10.1002\/14651858.CD014201-BIB0047|cit47","first-page":"40","article-title":"3-year analyses from spinart: Patient-and joint-level changes in magnetic resonance imaging scores with bayer's sucrose-formulated recombinant factor VIII (RFVIIIFS) in adolescents and adults previously treated on demand","volume":"21","author":"Lundin","year":"2015","journal-title":"Haemophilia"},{"key":"10.1002\/14651858.CD014201-BIB0048|cit48","doi-asserted-by":"crossref","unstructured":"Lundin B Hong W Raunig D Engelen S Peterfy C Werk M Effect on joint health of routine prophylaxis with Bayer's sucrose-formulated recombinant factor VIII (rFVIII-FS) in adolescents and adults previously treated on demand: MRI analyses from the 3-year Spinart Study 56th ASH Annual Meeting and Exposition; 2014 Dec 6-9; San Francisco, California 2014","DOI":"10.1182\/blood.V124.21.2854.2854"},{"issue":"1","key":"10.1002\/14651858.CD014201-BIB0049|cit49","first-page":"119","article-title":"Corrigendum to Randomized, controlled, parallel-group trial of routine prophylaxis vs. on-demand treatment with sucrose-formulated recombinant factor VIII in adults with severe hemophilia A (SPINART)","volume":"12","author":"Manco-Johnson","year":"2014","journal-title":"Journal of Thrombosis and Haemostasis"},{"key":"10.1002\/14651858.CD014201-BIB0050|cit50","first-page":"96","article-title":"3-year results from SPINART: prophylaxis vs on-demand treatment with sucrose-formulated recombinant factor VIII","volume":"20 Suppl 3","author":"Manco-Johnson","year":"2014","journal-title":"Haemophilia"},{"issue":"16","key":"10.1002\/14651858.CD014201-BIB0051|cit51","doi-asserted-by":"crossref","first-page":"1119","DOI":"10.1111\/jth.12202","article-title":"Randomized, controlled, parallel-group trial of routine prophylaxis vs. on-demand treatment with sucrose-formulated recombinant factor VIII in adults with severe hemophilia A (SPINART)","volume":"11","author":"Manco-Johnson","year":"2013","journal-title":"Journal of Thrombosis and Haemostasis"},{"issue":"11","key":"10.1002\/14651858.CD014201-BIB0052|cit52","doi-asserted-by":"crossref","first-page":"2115","DOI":"10.1111\/jth.13811","article-title":"Effect of late prophylaxis in hemophilia on joint status: a randomized trial","volume":"15","author":"Manco-Johnson","year":"2017","journal-title":"Journal of Thrombosis and Haemostasis"},{"key":"10.1002\/14651858.CD014201-BIB0053|cit53","unstructured":"Trial to evaluate the effect of secondary prophylaxis with rfviii therapy in severe hemophilia a adult and\/or adolescent subjects compared to that of episodic treatment clinicaltrials.gov\/show\/NCT00623480"},{"key":"10.1002\/14651858.CD014201-BIB0054|cit54","first-page":"51","article-title":"Spinart 3-year data: Patient-reported benefits of adult prophylaxis vs on-demand treatment with bayer's sucrose-formulated recombinant factor viii","volume":"21","author":"Pocoski","year":"2015","journal-title":"Haemophilia"},{"key":"10.1002\/14651858.CD014201-BIB0055|cit55","first-page":"20","article-title":"Spinart trial 3-year results: improved quality of life in adults using prophylaxis with Bayer's sucrose-formulated recombinant factor VIII","volume":"11 Suppl 2","author":"Pocoski","year":"2013","journal-title":"Journal of thrombosis and haemostasis : JTH"},{"key":"10.1002\/14651858.CD014201-BIB0056|cit56","first-page":"132","article-title":"Spinart trial 3-year results with bayer's sucrose-formulated recombinant factor VIII: relationship between bleeding frequency and joint health in adults with severe hemophilia A using prophylaxis","volume":"13 Suppl 2","author":"Reding","year":"2015","journal-title":"Journal of thrombosis and haemostasis : JTH"},{"key":"10.1002\/14651858.CD014201-BIB0057|cit57","first-page":"28","article-title":"Bleeding frequency subanalyses in a randomized controlled trial of prophylaxis vs on-demand treatment with sucrose-formulated recombinant factor VIII in adults with severe hemophilia A","volume":"19 Suppl 2","author":"Zarkova","year":"2013","journal-title":"Haemophilia"},{"issue":"5","key":"10.1002\/14651858.CD014201-BIB0058|cit58","doi-asserted-by":"crossref","first-page":"728","DOI":"10.1055\/s-0040-1709519","article-title":"Modeling to predict factor VIII levels associated with zero bleeds in patients with severe hemophilia a initiated on tertiary prophylaxis","volume":"120","author":"Chowdary","year":"2020","journal-title":"Thrombosis and Haemostasis"},{"key":"10.1002\/14651858.CD014201-BIB0059|cit59","unstructured":"Prophylaxis study of recombinant factor VIII manufactured protein-free (rahf-pfm) in patients with hemophilia a clinicaltrials.gov\/show\/NCT00243386 2005"},{"key":"10.1002\/14651858.CD014201-BIB0060|cit60","first-page":"1081","article-title":"Impact of rAHF-PFM prophylactic treatment on annual bleeding rate and health-related quality of life of adults with severe hemophilia A","volume":"11 Suppl 2","author":"Quon","year":"2013","journal-title":"Journal of thrombosis and haemostasis : JTH"},{"key":"10.1002\/14651858.CD014201-BIB0061|cit61","first-page":"827","article-title":"Significant improvement in health-related quality of life with prophylaxis in severe hemophilia A: results from the rAHF-PFM randomized, controlled prophylaxis study","volume":"9 Suppl 2","author":"Shapiro","year":"2011","journal-title":"Journal of thrombosis and haemostasis : JTH"},{"key":"10.1002\/14651858.CD014201-BIB0062|cit62","doi-asserted-by":"crossref","first-page":"359","DOI":"10.1111\/j.1538-7836.2011.04611.x","article-title":"A randomized comparison of two prophylaxis regimens and a paired comparison of on-demand and prophylaxis treatments in hemophilia A management","volume":"10","author":"Valentino","year":"2012","journal-title":"Journal of Thrombosis and Haemostasis"},{"issue":"5","key":"10.1002\/14651858.CD014201-BIB0063|cit63","doi-asserted-by":"crossref","first-page":"630","DOI":"10.1111\/hae.12382","article-title":"ADVATE prophylaxis: post hoc analysis of joint bleeding episodes","volume":"20","author":"Valentino","year":"2014","journal-title":"Haemophilia"},{"issue":"5","key":"10.1002\/14651858.CD014201-BIB0064|cit64","doi-asserted-by":"crossref","first-page":"630","DOI":"10.1111\/hae.12382","article-title":"ADVATE prophylaxis: post hoc analysis of joint bleeding episodes","volume":"20","author":"Valentino","year":"2014","journal-title":"Haemophilia"},{"key":"10.1002\/14651858.CD014201-BIB0065|cit65","first-page":"322","article-title":"Pharmacokinetic (PK) and clinical data support for effectiveness of once-weekly recombinant coagulation factor IX (RFIX) dosing for prophylaxis in patients with moderately severe or severe hemophilia B","volume":"13 Suppl 2","author":"Korth-Bradley","year":"2015","journal-title":"Journal of thrombosis and haemostasis : JTH"},{"key":"10.1002\/14651858.CD014201-BIB0066|cit66","doi-asserted-by":"crossref","unstructured":"Rendo P Barrette-Grischow MK Smith L Korth-Bradley JM Charnigo R Shafer FE Evaluation of two secondary prophylaxis regimens of recombinant factor IX (r-IX) in moderately severe to severe (FIX \u22642%) hemophilia B patients Blood 2012 120 21","DOI":"10.1182\/blood.V120.21.4628.4628"},{"key":"10.1002\/14651858.CD014201-BIB0067|cit67","first-page":"20","article-title":"Evaluation of two secondary prophylaxis regimens of recombinant factor IX (r-fix) in moderately severe to severe (fix a\u2030\u00a4 2%) hemophilia B patients","volume":"19 Suppl 2","author":"Rendo","year":"2013","journal-title":"Haemophilia"},{"issue":"3","key":"10.1002\/14651858.CD014201-BIB0068|cit68","doi-asserted-by":"crossref","first-page":"349","DOI":"10.1111\/hae.12305","article-title":"Lack of seasonal variation in bleeding and patient-assessed pain patterns in patients with haemophilia B receiving on-demand therapy","volume":"20","author":"Shafer","year":"2014","journal-title":"Haemophilia"},{"key":"10.1002\/14651858.CD014201-BIB0069|cit69","doi-asserted-by":"crossref","unstructured":"Shafer FE Smith L Vendetti N Rendo P Carr ME Lack of seasonal variation in bleeding and patient-assessed pain patterns in patients with hemophilia b receiving on-demand therapy Blood 2012 120 21","DOI":"10.1182\/blood.V120.21.1136.1136"},{"key":"10.1002\/14651858.CD014201-BIB0070|cit70","first-page":"357","article-title":"A multicenter, open-label study to compare on-demand treatment with two prophylaxis regimens of recombinant coagulation factor IX in subjects with hemophilia B","volume":"9 Suppl 2","author":"Valentino","year":"2011","journal-title":"Journal of thrombosis and haemostasis : JTH"},{"issue":"3","key":"10.1002\/14651858.CD014201-BIB0071|cit71","doi-asserted-by":"crossref","first-page":"398-406","DOI":"10.1111\/hae.12344","article-title":"Multicentre, randomized, open-label study of on-demand treatment with two prophylaxis regimens of recombinant coagulation factor IX in haemophilia B subjects","volume":"20","author":"Valentino","year":"2014","journal-title":"Haemophilia"},{"issue":"4","key":"10.1002\/14651858.CD014201-BIB0072|cit72","doi-asserted-by":"crossref","first-page":"391","DOI":"10.1111\/j.1365-2796.1994.tb00815.x","article-title":"A longitudinal study of orthopaedic outcomes for severe factor VIII deficient haemophiliacs","volume":"236","author":"Aledort","year":"1994","journal-title":"Journal of Internal Medicine"},{"key":"10.1002\/14651858.CD014201-BIB0073|cit73","first-page":"119","article-title":"Tolerability\/safety of feiba reconstituted in regular or 50% reduced volume and faster infusion rates: rationale and study design in patients with hemophilia A or B with inhibitors","volume":"24 Suppl 1","author":"Ali","year":"2018","journal-title":"Haemophilia"},{"issue":"23","key":"10.1002\/14651858.CD014201-BIB0074|cit74","doi-asserted-by":"crossref","first-page":"3532","DOI":"10.1182\/blood.V126.23.3532.3532","article-title":"Safety and efficacy of new nonacog alfa drug (innonafactor) in prophylactic treatment in patients with severe and moderate hemophilia B","volume":"126","author":"Andreeva","year":"2015","journal-title":"Blood"},{"issue":"23","key":"10.1002\/14651858.CD014201-BIB0075|cit75","doi-asserted-by":"crossref","first-page":"4690","DOI":"10.1182\/blood.V126.23.4690.4690","article-title":"Safety and efficiency of new nonacog alfa drug in the treatment of bleeding episodes in patients with severe and moderate hemophilia b","volume":"126","author":"Davydkin","year":"2015","journal-title":"Blood"},{"key":"10.1002\/14651858.CD014201-BIB0076|cit76","first-page":"982","article-title":"A prospective, open-label, randomized, parallel study with AICC to evaluate the efficacy and safety of prophylactic vs. on-demand treatment in hemophilia A or B subjects with inhibitors","volume":"11 Suppl 2","author":"Antunes","year":"2013","journal-title":"Journal of Thrombosis and Haemostasis"},{"key":"10.1002\/14651858.CD014201-BIB0077|cit77","doi-asserted-by":"crossref","first-page":"96","DOI":"10.1111\/hae.12246","article-title":"Comparison of historic on-demand versus prospective on-demand and prophylaxis bleeding episodes in hemophilia A and B patients with inhibitors treated with FEIBA NF","volume":"20","author":"Antunes","year":"2014","journal-title":"Haemophilia"},{"issue":"1","key":"10.1002\/14651858.CD014201-BIB0078|cit78","doi-asserted-by":"crossref","first-page":"65","DOI":"10.1111\/hae.12246","article-title":"Randomized comparison of prophylaxis and on-demand regimens with FEIBA NF in the treatment of haemophilia A and B with inhibitors","volume":"20","author":"Antunes","year":"2014","journal-title":"Haemophilia"},{"key":"10.1002\/14651858.CD014201-BIB0079|cit79","first-page":"719","article-title":"Health-related quality of life in hemophilia patients with inhibitors receiving prophylaxis with anti-inhibitor coagulant complex (AICC): results from the AICC prophylaxis study","volume":"11 Suppl 2","author":"Stasyshyn","year":"2013","journal-title":"Journal of thrombosis and haemostasis"},{"issue":"5","key":"10.1002\/14651858.CD014201-BIB0080|cit80","doi-asserted-by":"crossref","first-page":"644","DOI":"10.1111\/hae.12390","article-title":"Prophylaxis with anti-inhibitor coagulant complex improves health-related quality of life in haemophilia patients with inhibitors: results from FEIBA NF Prophylaxis Study","volume":"20","author":"Stasyshyn","year":"2014","journal-title":"Haemophilia"},{"issue":"4","key":"10.1002\/14651858.CD014201-BIB0081|cit81","doi-asserted-by":"crossref","first-page":"615","DOI":"10.1111\/hae.12873","article-title":"Pro- and anticoagulant factors facilitate thrombin generation and balance the haemostatic response to FEIBA in prophylactic therapy","volume":"22","author":"Varadi","year":"2016","journal-title":"Haemophilia"},{"key":"10.1002\/14651858.CD014201-BIB0082|cit82","unstructured":"Varadi K Tangada S Schrenk G Doralt J Ewenstein B Turecek P Evidence of APCC mode of action in a clinical study treating hemophilia A inhibitor patients with prophylaxis therapy Journal of Thrombosis and Haemostasis 2015"},{"issue":"3","key":"10.1002\/14651858.CD014201-BIB0083|cit83","doi-asserted-by":"crossref","first-page":"494","DOI":"10.1111\/hae.13953","article-title":"Recombinant factor VIII Fc fusion protein for the treatment of severe haemophilia A: final results from the ASPIRE extension study","volume":"26","author":"Nolan","year":"2020","journal-title":"Haemophilia"},{"issue":"1","key":"10.1002\/14651858.CD014201-BIB0084|cit84","doi-asserted-by":"crossref","first-page":"72","DOI":"10.1111\/hae.12766","article-title":"Long-term safety and efficacy of recombinant factor VIII Fc fusion protein (rFVIIIFc) in subjects with haemophilia A","volume":"22","author":"Nolan","year":"2016","journal-title":"Haemophilia"},{"issue":"4","key":"10.1002\/14651858.CD014201-BIB0085|cit85","doi-asserted-by":"crossref","first-page":"1109","DOI":"10.1046\/j.1365-2141.1999.01463.x","article-title":"Primary prophylaxis in severe haemophilia should be started at an early age but can be individualized","volume":"105","author":"Astermark","year":"1999","journal-title":"British Journal of Haematology"},{"issue":"Suppl 2","key":"10.1002\/14651858.CD014201-BIB0086|cit86","first-page":"1","article-title":"Subcutaneous prophylaxis with the anti-TFPI monoclonal antibody concizumab in hemophilia A and hemophilia A\/B with inhibitors: phase 2 trial results","volume":"3","author":"Astermark","year":"2019","journal-title":"Research and Practice in Thrombosis and Haemostasis"},{"key":"10.1002\/14651858.CD014201-BIB0087|cit87","unstructured":"A trial evaluating the efficacy and safety of prophylactic administration of concizumab in haemophilia a and b patients with inhibitors http:\/\/www.who.int\/trialsearch\/Trial2.aspx?TrialID=EUCTR2016-000510-30-ES"},{"key":"10.1002\/14651858.CD014201-BIB0088|cit88","doi-asserted-by":"crossref","unstructured":"Lee XY Cepo K Porstmann T Concizumab subcutaneous prophylaxis improves health-related quality-of-life measures in patients with congenital hemophilia with inhibitors: phase 2 trial results Blood 2019 134","DOI":"10.1182\/blood-2019-122827"},{"key":"10.1002\/14651858.CD014201-BIB0089|cit89","unstructured":"A trial evaluating the efficacy and safety of prophylactic administration of concizumab in haemophilia a and b patients with inhibitors clinicaltrials.gov\/show\/NCT03196284"},{"key":"10.1002\/14651858.CD014201-BIB0090|cit90","doi-asserted-by":"crossref","unstructured":"Shapiro A Castaman G Cepo K Hvitfeldt Poulsen L Hollensen C Matsushita T Efficacy and safety of subcutaneous prophylaxis with concizumab in patients with hemophilia A or B with inhibitors: results from explorer4, a phase 2, randomized, open-label, controlled trial Blood 2019 134","DOI":"10.1182\/blood-2019-122809"},{"issue":"22","key":"10.1002\/14651858.CD014201-BIB0091|cit91","doi-asserted-by":"crossref","first-page":"1973","DOI":"10.1182\/blood.2019001542","article-title":"Subcutaneous concizumab prophylaxis in hemophilia A and hemophilia A\/B with inhibitors: phase 2 trial results","volume":"134","author":"Shapiro","year":"2019","journal-title":"Blood"},{"issue":"21","key":"10.1002\/14651858.CD014201-BIB0092|cit92","doi-asserted-by":"crossref","first-page":"5433","DOI":"10.1182\/bloodadvances.2020002789","article-title":"The design of a Bayesian platform trial to prevent and eradicate inhibitors in patients with hemophilia","volume":"4","author":"Bertolet","year":"2020","journal-title":"Blood Advances"},{"key":"10.1002\/14651858.CD014201-BIB0093|cit93","unstructured":"The hemophilia inhibitor prevention trial clinicaltrials.gov\/show\/NCT04303559"},{"key":"10.1002\/14651858.CD014201-BIB0094|cit94","first-page":"75","article-title":"Health-related quality of life in previously treated severe haemophilia a patients with extended half-life, pegylated, full-length, recombinant factor VIII (BAX855) prophylaxis","volume":"23","author":"Booth","year":"2017","journal-title":"Haemophilia"},{"issue":"5","key":"10.1002\/14651858.CD014201-BIB0095|cit95","first-page":"251","article-title":"Long-term therapy and on-demand treatment of children and adolescents with severe haemophilia A: 12 years of experience","volume":"22","author":"Brackmann","year":"1992","journal-title":"Haemostasis"},{"key":"10.1002\/14651858.CD014201-BIB0096|cit96","first-page":"16","article-title":"Clinical experience of pharmacokinetic dosing of Factor VIII for prophylaxis","volume":"2 Suppl 1","author":"Carlsson","year":"1996","journal-title":"Haemophilia"},{"issue":"2","key":"10.1002\/14651858.CD014201-BIB0097|cit97","doi-asserted-by":"crossref","first-page":"96","DOI":"10.1046\/j.1365-2516.1997.00091.x","article-title":"Improved cost-effectiveness by pharmacokinetic dosing of factor VIII in prophylactic treatment of haemophilia A","volume":"3","author":"Carlsson","year":"1997","journal-title":"Haemophilia"},{"issue":"1","key":"10.1002\/14651858.CD014201-BIB0098|cit98","first-page":"68","article-title":"Effect of low dose prophylaxis versus episodic treatment on joint events in severe hemophilia a patients above 2 years: a randomized open label pilot study in Eastern India","volume":"34","author":"Chakraborty","year":"2018","journal-title":"Indian Journal of Hematology & Blood Transfusion"},{"key":"10.1002\/14651858.CD014201-BIB0099|cit99","first-page":"460","article-title":"A new treatment concept for haemophilia: Safety, pharmacokinetics and pharmacodynamics of single i.v. and s.c. Doses of a monoclonal anti-TFPI antibody in healthy males and haemophilia subjects","volume":"11 Suppl 2","author":"Chowdary","year":"2013","journal-title":"Journal of thrombosis and haemostasis"},{"issue":"5","key":"10.1002\/14651858.CD014201-BIB0100|cit100","doi-asserted-by":"crossref","first-page":"743","DOI":"10.1111\/jth.12864","article-title":"Safety and pharmacokinetics of anti-TFPI antibody (concizumab) in healthy volunteers and patients with hemophilia: a randomized first human dose trial","volume":"13","author":"Chowdary","year":"2015","journal-title":"Journal of thrombosis and haemostasis : JTH"},{"key":"10.1002\/14651858.CD014201-BIB0101|cit101","first-page":"118","article-title":"Phase 1 and phase 1\/2 extension study of fitusiran, an investigational rnai therapeutic targeting antithrombin for the treatment of hemophilia: updated results in patients without inhibitors","volume":"23 Suppl 2","author":"Chowdary","year":"2017","journal-title":"Haemophilia"},{"key":"10.1002\/14651858.CD014201-BIB0102|cit102","first-page":"88","article-title":"Phase 1 and phase 1\/2 extension study of fitusiran, an investigational rnai therapeutic targeting antithrombin for the treatment of hemophilia: updated results in patients with inhibitors","volume":"23 Suppl 2","author":"Pasi","year":"2017","journal-title":"Haemophilia"},{"key":"10.1002\/14651858.CD014201-BIB0103|cit103","first-page":"94","article-title":"Low-dose prophylaxis versus on-demand treatment in Indonesian children with severe hemophilia A: an interim report","volume":"24 Suppl 5","author":"Chozie","year":"2018","journal-title":"Haemophilia"},{"issue":"4","key":"10.1002\/14651858.CD014201-BIB0104|cit104","doi-asserted-by":"crossref","first-page":"633","DOI":"10.1111\/hae.13770","article-title":"Comparison of the efficacy and safety of 12-month low-dose factor VIII tertiary prophylaxis vs on-demand treatment in severe haemophilia A children","volume":"25","author":"Chozie","year":"2019","journal-title":"Haemophilia"},{"issue":"2","key":"10.1002\/14651858.CD014201-BIB0105|cit105","first-page":"243","article-title":"Prophylactic treatment for haemophilia A patients: a pilot study","volume":"26","author":"Chuansumrit","year":"1995","journal-title":"Southeast Asian Journal of Tropical Medicine of Public Health"},{"issue":"1","key":"10.1002\/14651858.CD014201-BIB0106|cit106","doi-asserted-by":"crossref","first-page":"83","DOI":"10.1111\/j.1538-7836.2009.03650.x","article-title":"Efficacy and safety of secondary prophylactic vs. on-demand sucrose-formulated recombinant factor VIII treatment in adults with severe hemophilia A: results from a 13-month crossover study","volume":"8","author":"Collins","year":"2010","journal-title":"Journal of Thrombosis and Haemostasis"},{"key":"10.1002\/14651858.CD014201-BIB0107|cit107","first-page":"119","article-title":"Improvement in health status and quality of life in patients with haemophilia B treated with nonacog beta pegol, an extended half-life glycopegylated recombinant FIX product","volume":"22 Suppl 4","author":"Chowdary","year":"2016","journal-title":"Haemophilia"},{"issue":"4","key":"10.1002\/14651858.CD014201-BIB0108|cit108","doi-asserted-by":"crossref","first-page":"e267","DOI":"10.1111\/hae.12995","article-title":"Improvement in health-related quality of life in patients with haemophilia B treated with nonacog beta pegol, a new extended half-life recombinant FIX product","volume":"22","author":"Chowdary","year":"2016","journal-title":"Haemophilia"},{"key":"10.1002\/14651858.CD014201-BIB0109|cit109","first-page":"19","article-title":"Safety, efficacy and pharmacokinetics of nonacog beta pegol (N9-GP) for prophylaxis and treatment of bleeding episodes in patients with haemophilia B","volume":"11 Suppl","author":"Collins","year":"2013","journal-title":"Journal of thrombosis and haemostasis : JTH"},{"issue":"26","key":"10.1002\/14651858.CD014201-BIB0110|cit110","doi-asserted-by":"crossref","first-page":"3880","DOI":"10.1182\/blood-2014-05-573055","article-title":"Recombinant long-acting glycoPEGylated factor IX in hemophilia B: a multinational randomized phase 3 trial","volume":"124","author":"Collins","year":"2014","journal-title":"Blood"},{"issue":"9","key":"10.1002\/14651858.CD014201-BIB0111|cit111","first-page":"E417","article-title":"Prophylactic efficacy of nonacog beta pegol once weekly in adult and pediatric patients with hemophilia B: a pooled analysis","volume":"91","author":"Escobar","year":"2016","journal-title":"American Journal of Hematology"},{"key":"10.1002\/14651858.CD014201-BIB0112|cit112","unstructured":"A multi-centre, single-blind trial evaluating safety and efficacy, including pharmacokinetics, of NNC-0156-0000-0009 when used for treatment and prophylaxis of bleeding episodes in patients with haemophilia B - Paradigm\u21222 www.who.int\/trialsearch\/Trial2.aspx?TrialID=EUCTR2010-023069-24-NL"},{"key":"10.1002\/14651858.CD014201-BIB0113|cit113","unstructured":"Safety and efficacy of NNC-0156-0000-0009 in haemophilia b patients clinicaltrials.gov\/show\/NCT01333111 2011"},{"key":"10.1002\/14651858.CD014201-BIB0114|cit114","first-page":"316","article-title":"Recombinant long-acting glycopegylated factor IX (nonacog beta pegol) in hemophilia B: assessment of target joints in the multinational randomized phase 3 clinical trial","volume":"13 Suppl 2","author":"Negrier","year":"2015","journal-title":"Journal of thrombosis and haemostasis : JTH"},{"issue":"4","key":"10.1002\/14651858.CD014201-BIB0115|cit115","doi-asserted-by":"crossref","first-page":"507","DOI":"10.1111\/hae.12902","article-title":"Recombinant long-acting glycoPEGylated factor IX (nonacog beta pegol) in haemophilia B: assessment of target joints in multinational phase 3 clinical trials","volume":"22","author":"Negrier","journal-title":"Haemophilia"},{"issue":"6","key":"10.1002\/14651858.CD014201-BIB0116|cit116","doi-asserted-by":"crossref","first-page":"911","DOI":"10.1111\/hae.13608","article-title":"Once-weekly prophylaxis with 40 IU\/kg nonacog beta pegol (N9-GP) achieves trough levels of >15% in patients with haemophilia B: pooled data from the ParadigmTM trials","volume":"24","author":"Oldenburg","year":"2018","journal-title":"Haemophilia"},{"key":"10.1002\/14651858.CD014201-BIB0117|cit117","first-page":"s741","article-title":"Prophylactic efficacy of nonacog beta pegol once weekly in adult and pediatric patients with hemophilia B: a pooled analysis","volume":"14 Suppl 5","author":"Santagostino","year":"2016","journal-title":"Blood Transfusion"},{"key":"10.1002\/14651858.CD014201-BIB0118|cit118","first-page":"100","article-title":"Pharmacokinetics of a novel extended half-life glycoPEGylated factor IX, nonacog beta pegol (N9-GP) in previously treated adult, adolescent, and paediatric patients with haemophilia B-Results from two phase 3 trials","volume":"22","author":"Tiede","year":"2016","journal-title":"Haemophilia"},{"issue":"9","key":"10.1002\/14651858.CD014201-BIB0119|cit119","first-page":"E415","article-title":"Nonacog beta pegol for the perioperative management of minor surgery in patients with hemophilia B: results from the ParadigmTM4 clinical trial","volume":"91","author":"Walsh","year":"2016","journal-title":"American Journal of Hematology"},{"key":"10.1002\/14651858.CD014201-BIB0120|cit120","first-page":"79","article-title":"Beyond ABR: high fix activity translates into clinical benefits","volume":"24 Suppl 1","author":"Young","year":"2018","journal-title":"Haemophilia"},{"issue":"9","key":"10.1002\/14651858.CD014201-BIB0121|cit121","first-page":"E75","article-title":"Safety and efficacy of N9-GP, A recombinant glycopegylated factor IX with extended half-life, in us vs global patients with hemophilia B: results from the ParadigmTM clinical program","volume":"93","author":"Young","year":"2018","journal-title":"American Journal of Hematology"},{"issue":"2 Suppl 4","key":"10.1002\/14651858.CD014201-BIB0122|cit122","doi-asserted-by":"crossref","first-page":"52","DOI":"10.1016\/S0037-1963(01)90109-X","article-title":"Clinical evaluation of B-domain deleted recombinant factor VIII in previously untreated patients","volume":"38","author":"Courter","year":"2001","journal-title":"Seminars in Hematology"},{"key":"10.1002\/14651858.CD014201-BIB0123|cit123","first-page":"92","article-title":"Simple and fixed N8-GP dosing regimen associated with measurable trough levels and low annualised bleed rates in children and adolescents\/adults treated with N8-GP prophylaxis","volume":"24 Suppl 5","author":"Carcao","year":"2018","journal-title":"Haemophilia"},{"key":"10.1002\/14651858.CD014201-BIB0124|cit124","first-page":"266","article-title":"N8-GP treatment sustains low bleeding rates in patients with haemophilia A","volume":"3","author":"Chowdary","year":"2019","journal-title":"Research and Practice in Thrombosis and Haemostasis"},{"key":"10.1002\/14651858.CD014201-BIB0125|cit125","doi-asserted-by":"crossref","first-page":"1177","DOI":"10.1182\/blood-2018-99-110308","article-title":"Efficacy of an extended half-life glycoPEGylated rFVIII (N8-GP): pooled analysis of ABR (results from two clinical trials)","volume":"132 Suppl 1","author":"Chowdary","year":"2018","journal-title":"Blood"},{"issue":"3","key":"10.1002\/14651858.CD014201-BIB0126|cit126","doi-asserted-by":"crossref","first-page":"373","DOI":"10.1111\/hae.13712","article-title":"Once-weekly prophylaxis with glycoPEGylated recombinant factor VIII (N8-GP) in severe haemophilia A: safety and efficacy results from Pathfinder 2 (randomized phase III trial)","volume":"25","author":"Curry","year":"2019","journal-title":"Haemophilia"},{"key":"10.1002\/14651858.CD014201-BIB0127|cit127","first-page":"730","article-title":"Once-weekly prophylaxis with GlycoPEGylated recombinant factor VIII (N8-GP) in severe haemophilia A: safety and efficacy results from a randomised phase 3 trial (PathfinderTM2)","volume":"1 Suppl 1","author":"Curry","year":"2017","journal-title":"Research and Practice in Thrombosis and Haemostasis"},{"key":"10.1002\/14651858.CD014201-BIB0128|cit128","first-page":"420","article-title":"Long-term safety of N8-GP (turoctocog alfa pegol) prophylaxis in patients with severe haemophilia A","volume":"3","author":"Curry","year":"2019","journal-title":"Research and Practice in Thrombosis and Haemostasis"},{"issue":"Suppl 1","key":"10.1002\/14651858.CD014201-BIB0129|cit129","first-page":"434","article-title":"Prophylaxis with turoctocog alfa pegol (N8-GP) maintains improvements in health-related quality of life (HRQoL) and treatment satisfaction (TS) over \u2265 4.5 years in patients with haemophilia A (HA)","volume":"4","author":"Giangrande","year":"2020","journal-title":"Research and practice in thrombosis and haemostasis"},{"key":"10.1002\/14651858.CD014201-BIB0130|cit130","first-page":"41","article-title":"Efficacy and PK of turoctocog alfa pegol in patients with severe haemophilia A: results from 4 clinical trials","volume":"25","author":"Tiede","year":"2019","journal-title":"Haemophilia"},{"issue":"23","key":"10.1002\/14651858.CD014201-BIB0131|cit131","doi-asserted-by":"crossref","first-page":"3532","DOI":"10.1182\/blood.V126.23.3532.3532","article-title":"Safety and efficacy of new nonacog alfa drug (innonafactor) in prophylactic treatment in patients with severe and moderate hemophilia b","volume":"126","author":"Andreeva","year":"2015","journal-title":"Blood"},{"issue":"23","key":"10.1002\/14651858.CD014201-BIB0132|cit132","doi-asserted-by":"crossref","first-page":"4690","DOI":"10.1182\/blood.V126.23.4690.4690","article-title":"Safety and efficiency of new nonacog alfa drug in the treatment of bleeding episodes in patients with severe and moderate hemophilia b","volume":"126","author":"Davydkin","year":"2015","journal-title":"Blood"},{"issue":"4","key":"10.1002\/14651858.CD014201-BIB0133|cit133","doi-asserted-by":"crossref","first-page":"630","DOI":"10.1055\/s-0038-1650635","article-title":"Radiological score in paediatric haemophilic patients with early and late onset of factor VIII-prophylaxis","volume":"76","author":"Dzinaj","year":"1996","journal-title":"Thrombosis Haemostasis"},{"issue":"11","key":"10.1002\/14651858.CD014201-BIB0134|cit134","doi-asserted-by":"crossref","first-page":"2184","DOI":"10.1111\/jth.14272","article-title":"A randomized trial of safety, pharmacokinetics and pharmacodynamics of concizumab in people with hemophilia A","volume":"16","author":"Eichler","year":"2018","journal-title":"Journal of thrombosis and Haemostasis"},{"issue":"Suppl 2","key":"10.1002\/14651858.CD014201-BIB0135|cit135","first-page":"1","article-title":"Evaluation of safety and establishment of a PK\/PD relationship of concizumab in hemophilia a patients","volume":"1","author":"Eichler","year":"2017","journal-title":"Research and Practice in Thrombosis and Haemostasis"},{"key":"10.1002\/14651858.CD014201-BIB0136|cit136","unstructured":"Trial investigating safety, pharmacokinetics and pharmacodynamics of concizumab administered subcutaneously to haemophilia a subjects clinicaltrials.gov\/show\/NCT02490787 2015"},{"key":"10.1002\/14651858.CD014201-BIB0137|cit137","unstructured":"An Investigator-sponsored study on rFVIIa prophylaxis in children with haemophilia A and inhibitors - ENJOIH 01 www.who.int\/trialsearch\/Trial2.aspx?TrialID=EUCTR2009-010172-21-IT"},{"issue":"2","key":"10.1002\/14651858.CD014201-BIB0138|cit138","first-page":"407","article-title":"European Initiative to prevent joint damage in haemophilia children with inhibitors (ENJOIH) - a prospective study","volume":"16","author":"Santagostino","year":"2010","journal-title":"Haemophilia"},{"key":"10.1002\/14651858.CD014201-BIB0139|cit139","first-page":"78","article-title":"European initiative to prevent joint damage in haemophilia children with inhibitors (ENJOIH) - a prospective study","volume":"16 Suppl 4","author":"Santagostino","year":"2010","journal-title":"Haemophilia"},{"key":"10.1002\/14651858.CD014201-BIB0140|cit140","first-page":"4","article-title":"European initiative to prevent joint damage in haemophilia children with inhibitors (ENJOIH) - a prospective study","volume":"18 Suppl 1","author":"Santagostino","year":"2012","journal-title":"Haemophilia"},{"issue":"2","key":"10.1002\/14651858.CD014201-BIB0141|cit141","doi-asserted-by":"crossref","first-page":"268","DOI":"10.1002\/rth2.12192","article-title":"Favorable pharmacokinetics in hemophilia B for nonacog beta pegol versus recombinant factor IX-Fc fusion protein: a randomized trial","volume":"3","author":"Escuriola Ettingshausen","year":"2019","journal-title":"Research and Practice in Thrombosis and Haemostasis"},{"key":"10.1002\/14651858.CD014201-BIB0142|cit142","doi-asserted-by":"crossref","unstructured":"Fusco F Gringeri A Riva S Leissinger C Mackensen S Mannucci PM Direct costs of children with haemophilia A undergoing prophylaxis or episodic treatment: results from the ESPRIT study 16th Congress of the European Hematology Association; 2011 June 9-12; London, UK 2011","DOI":"10.1111\/j.1538-7836.2011.04214.x"},{"key":"10.1002\/14651858.CD014201-BIB0143|cit143","first-page":"927","article-title":"Direct costs of children with haemophilia A undergoing prophylaxis or episodic treatment: results from the ESPRIT study","volume":"9 Suppl 2","author":"Gringeri","year":"2011","journal-title":"Journal of Thrombosis and Haemostasis"},{"key":"10.1002\/14651858.CD014201-BIB0144|cit144","first-page":"29","article-title":"A randomized clinical trial on prophylaxis Vs. episodic treatment in children with haemophilia A: the ESPRIT study","volume":"16 Suppl 4","author":"Gringeri","year":"2010","journal-title":"Haemophilia"},{"issue":"4","key":"10.1002\/14651858.CD014201-BIB0145|cit145","doi-asserted-by":"crossref","first-page":"700","DOI":"10.1111\/j.1538-7836.2011.04214.x","article-title":"A randomized clinical trial of prophylaxis in children with hemophilia A (the ESPRIT Study)","volume":"9","author":"Gringeri","year":"2011","journal-title":"Journal of Thrombosis and Haemostasis"},{"key":"10.1002\/14651858.CD014201-BIB0146|cit146","unstructured":"Gringeri A Lundin B von Mackensen S Mantovani LG Mannucci PM Bianchi Bonomi A Primary and secondary prophylaxis in children with haemophilia A reduces bleeding frequency and arthropathy development compared to on-demand treatment: a 10-year, randomized, clinical trial XXII Congress of the International Society on Thrombosis and Haemostasis (ISTH); 2009 Jul 11-16; Boston, MA, USA 2009"},{"key":"10.1002\/14651858.CD014201-BIB0147|cit147","first-page":"173","article-title":"A randomized, controlled trial on prophylaxis in children with haemophilia a: the E.S.P.R.I.T. study","volume":"Suppl 1","author":"Gringeri","year":"2002","journal-title":"Hematology Journal"},{"issue":"3","key":"10.1002\/14651858.CD014201-BIB0148|cit148","first-page":"171","article-title":"Evaluation study on prophylaxis: a randomised Italian trial (ESPRIT). One year report","volume":"4","author":"Gringeri","year":"1998","journal-title":"Haemophilia"},{"key":"10.1002\/14651858.CD014201-BIB0149|cit149","doi-asserted-by":"crossref","first-page":"38","DOI":"10.1046\/j.1365-2516.9.s1.6.x","article-title":"Prospective controlled studies on prophylaxis: An Italian approach","volume":"9 Suppl 1","author":"Gringeri","year":"2003","journal-title":"Haemophilia"},{"key":"10.1002\/14651858.CD014201-BIB0150|cit150","first-page":"19","article-title":"The Italian randomized evaluation of prophylaxis","volume":"6 Suppl 2","author":"Gringeri","year":"2000","journal-title":"Haemophilia"},{"key":"10.1002\/14651858.CD014201-BIB0151|cit151","first-page":"19","article-title":"Direct costs of children with haemophilia A undergoing prophylaxis or episodic treatment: results from the ESPRIT study","volume":"18 Suppl 1","author":"Riva","year":"2012","journal-title":"Haemophilia"},{"key":"10.1002\/14651858.CD014201-BIB0152|cit152","first-page":"29","article-title":"HR-QoL in children with hemophilia A: results from the ESPRIT study","volume":"18 Suppl 1","author":"Riva","year":"2012","journal-title":"Haemophilia"},{"key":"10.1002\/14651858.CD014201-BIB0153|cit153","first-page":"745","article-title":"Quality of life of children with hemophilia A undergoing prophylaxis or episodic treatment: results from the ESPRIT study","volume":"9 Suppl 2","author":"Mackensen","year":"2011","journal-title":"Journal of Thrombosis and Haemostasis"},{"issue":"6","key":"10.1002\/14651858.CD014201-BIB0154|cit154","doi-asserted-by":"crossref","first-page":"1228","DOI":"10.1111\/j.1538-7836.2006.01953.x","article-title":"Tailored prophylaxis in severe hemophilia A: interim results from the first 5 years of the Canadian Hemophilia Primary Prophylaxis Study","volume":"4","author":"Feldman","year":"2006","journal-title":"Journal of Thrombosis and Haemostasis"},{"issue":"6","key":"10.1002\/14651858.CD014201-BIB0155|cit155","doi-asserted-by":"crossref","first-page":"868","DOI":"10.1111\/hae.13312","article-title":"The pharmacokinetics and pharmacodynamics of single-dose and multiple-dose recombinant activated factor VII in patients with haemophilia A or B","volume":"23","author":"Fernandez-Bello","year":"2017","journal-title":"Haemophilia"},{"key":"10.1002\/14651858.CD014201-BIB0156|cit156","first-page":"OR205","article-title":"Late prophylaxis for severe hemophilia: effects of prophylaxis started in adulthood","volume":"3 Suppl 1","author":"Fischer","year":"2005","journal-title":"Journal of Thrombosis and Haemostasis"},{"key":"10.1002\/14651858.CD014201-BIB0157|cit157","first-page":"724","article-title":"Factor VIII (FVIII) inhibitor testing using a validated chromogenic bethesda assay (CBA) in HAVEN 1 (BH29884), a Phase 3 trial of emicizumab in persons with hemophilia a (PwHA) with inhibitors","volume":"1 Suppl 1","author":"Adamkewicz","year":"2017","journal-title":"Research and Practice in Thrombosis and Haemostasis"},{"key":"10.1002\/14651858.CD014201-BIB0158|cit158","first-page":"129","article-title":"Use of bypassing agents prior to and post bypassing agent dosing guidance during emicizumab prophylaxis: Analyses from the haven 1 study.","volume":"181","author":"Callaghan","journal-title":"British Journal of Haematology"},{"issue":"9","key":"10.1002\/14651858.CD014201-BIB0159|cit159","first-page":"E10","article-title":"Characterization of the impact of prior iti on patient outcomes in haven1","volume":"93","author":"Callaghan","year":"2018","journal-title":"American Journal of Hematology"},{"key":"10.1002\/14651858.CD014201-BIB0160|cit160","first-page":"3668","article-title":"Use of bypassing agents prior to and post bypassing agent dosing guidance during emicizumab prophylaxis: analyses from the HAVEN 1 study","volume":"130 Suppl 1","author":"Callaghan","year":"2017","journal-title":"Blood"},{"key":"10.1002\/14651858.CD014201-BIB0161|cit161","first-page":"128","article-title":"Surgical experience in two multicentre, openlabel phase 3 studies of emicizumab in persons with haemophilia a with inhibitors (HAVEN 1 and HAVEN 2)","volume":"181\u00a0Suppl 1","author":"Kruse-Jarres","year":"2018","journal-title":"British Journal of Haematology"},{"key":"10.1002\/14651858.CD014201-BIB0162|cit162","doi-asserted-by":"crossref","first-page":"89","DOI":"10.1182\/blood.V130.Suppl_1.89.89","article-title":"Surgical Experience in Two Multicenter, Open-Label Phase 3 Studies of Emicizumab in Persons with Hemophilia A with Inhibitors (HAVEN 1 and HAVEN 2)","volume":"130 Suppl 1","author":"Kruse-Jarres","year":"2017","journal-title":"Blood"},{"issue":"9","key":"10.1002\/14651858.CD014201-BIB0163|cit163","doi-asserted-by":"crossref","first-page":"1470","DOI":"10.1111\/jth.14491","article-title":"Safety analysis of rFVIIa with emicizumab dosing in congenital hemophilia A with inhibitors: experience from the HAVEN clinical program","volume":"17","author":"Levy","year":"2019","journal-title":"Journal of Thrombosis and Haemostasis : JTH"},{"key":"10.1002\/14651858.CD014201-BIB0164|cit164","first-page":"1071","article-title":"Emicizumab prophylaxis in adolescent\/adult patients with hemophilia a previously receiving episodic or prophylactic bypassing agent treatment: updated analyses from the haven 1 study","volume":"130 Suppl 1","author":"Mancuso","year":"2017","journal-title":"Blood"},{"key":"10.1002\/14651858.CD014201-BIB0165|cit165","first-page":"127","article-title":"Emicizumab prophylaxis in adolescent\/adult patients with haemophilia a previously receiving episodic or prophylactic bypassing agent treatment: updated analyses from the HAVEN 1 study","volume":"181 Suppl 1","author":"Mancuso","year":"2018","journal-title":"British Journal of Haematology"},{"key":"10.1002\/14651858.CD014201-BIB0166|cit166","unstructured":"A study to evaluate the efficacy, safety, and pharmacokinetics of prophylactic emicizumab versus no prophylaxis in hemophilia a participants with inhibitors www.clinicaltrials.gov\/show\/nct02622321"},{"key":"10.1002\/14651858.CD014201-BIB0167|cit167","first-page":"A6","article-title":"Efficacy, safety and pharmacokinetics (PK) of emicizumab (ACE910) prophylaxis (Px) in persons with haemophilia A with inhibitors (PwHAwl): randomized, multicenter, open-label, phase 3 study (HAVEN 1)","volume":"38 Suppl 1","author":"Oldenburg","year":"2018","journal-title":"Hamostaseologie"},{"issue":"1","key":"10.1002\/14651858.CD014201-BIB0168|cit168","doi-asserted-by":"crossref","first-page":"33","DOI":"10.1111\/hae.13618","article-title":"The effect of emicizumab prophylaxis on health-related outcomes in persons with haemophilia A with inhibitors: HAVEN 1 Study","volume":"25","author":"Oldenburg","year":"2019","journal-title":"Haemophilia"},{"issue":"9","key":"10.1002\/14651858.CD014201-BIB0169|cit169","doi-asserted-by":"crossref","first-page":"809","DOI":"10.1056\/NEJMoa1703068","article-title":"Emicizumab\u00a0prophylaxis in hemophilia A with inhibitors","volume":"377","author":"Oldenburg","year":"2017","journal-title":"New England Journal of Medicine"},{"key":"10.1002\/14651858.CD014201-BIB0170|cit170","first-page":"27","article-title":"Pharmacokinetics (PK), PK\/PD relationships of emicizumab in persons with haemophilia a (PWHA) with inhibitors from adolescent\/adult (HAVEN 1) and paediatric (HAVEN 2) phase 3 studies","volume":"24\u00a0Suppl 1","author":"Schmitt","year":"2018","journal-title":"Haemophilia"},{"key":"10.1002\/14651858.CD014201-BIB0171|cit171","first-page":"465","article-title":"Does variation between label and actual potency of factor VIII concentrate vials affect results of pharmacokinetic (PK)-guided dosing of replacement therapy in hemophilia A","volume":"4 (Suppl 1)","author":"Goedhart","year":"2020","journal-title":"Research and Practice in Thrombosis and Haemostasis"},{"issue":"3","key":"10.1002\/14651858.CD014201-BIB0172|cit172","doi-asserted-by":"crossref","first-page":"639","DOI":"10.1160\/TH14-11-0925","article-title":"The \"OPTI-CLOT\" trial. A randomised controlled trial on periOperative PharmacokineTIc-guided dosing of CLOTting factor concentrate in haemophilia A","volume":"114","author":"Hazendonk","year":"2015","journal-title":"Thrombosis and Haemostasis"},{"key":"10.1002\/14651858.CD014201-BIB0173|cit173","first-page":"84","article-title":"Von Willebrand factor and its effect on FVIII clearance in perioperative hemophilia a patients","volume":"26","author":"Van Moort","year":"2020","journal-title":"Haemophilia"},{"key":"10.1002\/14651858.CD014201-BIB0174|cit174","first-page":"438","article-title":"A randomized controlled trial: pharmacokinetic-guided dosing of factor VIII concentrate versus standard replacement therapy in perioperative hemophilia A patients (OPTI-CLOT Trial)","volume":"4 Suppl 1","author":"Van Moort","year":"2020","journal-title":"Research and Practice in Thrombosis and Haemostasis"},{"issue":"3","key":"10.1002\/14651858.CD014201-BIB0175|cit175","first-page":"563","article-title":"Phase III randomized, controlled trial of pre-emptive vs. standard prophylaxis to prevent inhibitor formation in children with severe hemophilia A: The inhibit study","volume":"17","author":"Ragni","year":"2011","journal-title":"Haemophilia"},{"key":"10.1002\/14651858.CD014201-BIB0176|cit176","doi-asserted-by":"crossref","unstructured":"Ragni MV Malec LM Design of the INHIBITOR trial: preventing inhibitors by avoiding 'danger', prolonging half-life and promoting tolerance Expert Review of Hematology 2014 7 6 747 55","DOI":"10.1586\/17474086.2014.963550"},{"key":"10.1002\/14651858.CD014201-BIB0177|cit177","unstructured":"Ragni MV Feasibility of the Hemophilia INHIBIT trial grantome.com\/grant\/NIH\/U34-HL114674-02"},{"issue":"2","key":"10.1002\/14651858.CD014201-BIB0178|cit178","doi-asserted-by":"crossref","first-page":"151","DOI":"10.3109\/08880019709030901","article-title":"Prophylactic therapy for hemophilia in a developing country, Turkey","volume":"14","author":"Kavakli","year":"1997","journal-title":"Pediatric Hematology and Oncology"},{"key":"10.1002\/14651858.CD014201-BIB0179|cit179","first-page":"68","article-title":"Overview of the clinical development program swift for the VWF\/FVIII concentrate voncento in haemophila a and von willebrand disease","volume":"23","author":"Auerswald","year":"2017","journal-title":"Haemophilia"},{"key":"10.1002\/14651858.CD014201-BIB0180|cit180","unstructured":"Khayat C Iosava G Romashevskaya I Aleinikova O Stasyshyn O Vashchenko L Efficacy and safety results of a phase 3, open label, multicentre study with Voncento in paediatric haemophilia A subjects < 12 years of age (SWIFTLY-HA study) Hamostaseologie 2016 36 A54"},{"key":"10.1002\/14651858.CD014201-BIB0181|cit181","first-page":"16","article-title":"Efficacy, safety and pharmacokinetic results of a phase II\/III, multicentre, double-blinded, randomized, cross-over study with a plasma-derived von Willebrand Factor (VWF)\/factorVIII (FVIII) concentrate (Voncento\u00ae) in subjects with hemophilia A (the SWIFT-HA study)","volume":"20 Suppl 3","author":"Klukowska","year":"2014","journal-title":"Haemophilia"},{"key":"10.1002\/14651858.CD014201-BIB0182|cit182","first-page":"841","article-title":"A phase III, open-label, multicentre study to evaluate efficacy and safety of a plasma-derived von Willebrand factor\/ factor VIII concentrate in pediatric subjects with hemophilia A (Swiftly-HA study)","volume":"13 Suppl 2","author":"Pompa","year":"2015","journal-title":"Journal of thrombosis and haemostasis : JTH"},{"issue":"2","key":"10.1002\/14651858.CD014201-BIB0183|cit183","doi-asserted-by":"crossref","first-page":"e75","DOI":"10.1016\/S2352-3026(16)30193-4","article-title":"Recombinant factor IX Fc fusion protein in children with haemophilia B (Kids B-LONG): results from a multicentre non-randomised phase 3 study","volume":"4","author":"Fischer","year":"2017","journal-title":"Lancet Haematology"},{"key":"10.1002\/14651858.CD014201-BIB0184|cit184","first-page":"75","article-title":"Health-related quality of life in previously treated severe haemophilia a patients with extended half-life, pegylated, full-length, recombinant factor VIII (BAX855) prophylaxis","volume":"23","author":"Booth","year":"2017","journal-title":"Haemophilia"},{"key":"10.1002\/14651858.CD014201-BIB0185|cit185","first-page":"364","article-title":"Patient preferences for FVIII and BAX 855: results from the BAX 855 pivotal trial","volume":"13 Suppl 2","author":"Epstein","year":"2015","journal-title":"Journal of Thrombosis and Haemostasis"},{"key":"10.1002\/14651858.CD014201-BIB0186|cit186","first-page":"356","article-title":"Bleeding patterns evaluated during prophylaxis with a full-length pegylated recombinant factor VIII (bax 855) with extended half-life in hemophilia A","volume":"13 Suppl 2","author":"Konkle","year":"2015","journal-title":"Journal of Thrombosis and Haemostasis : JTH"},{"key":"10.1002\/14651858.CD014201-BIB0187|cit187","first-page":"30","article-title":"Results of a pivotal clinical trial evaluating a full-length pegylated recombinant factor VIII (Peg-RFVIII) with extended half-life in haemophilia A","volume":"21 Suppl 2","author":"Konkle","year":"2015","journal-title":"Haemophilia"},{"key":"10.1002\/14651858.CD014201-BIB0188|cit188","first-page":"99","article-title":"Bleeding patterns during prophylaxis with a full-length pegylated recombinant factor VIII (Bax 855) with extended half-life in hemophilia a","volume":"22 Suppl 2","author":"Konkle","year":"2016","journal-title":"Haemophilia"},{"issue":"23","key":"10.1002\/14651858.CD014201-BIB0189|cit189","doi-asserted-by":"crossref","first-page":"1105","DOI":"10.1182\/blood.V126.23.1105.1105","article-title":"Characteristics of patients without bleeding in a pivotal trial of extended half-life, pegylated, full-length recombinant factor VIII (BAX 855) in the treatment of hemophilia a","volume":"126","author":"Ma","year":"2015","journal-title":"Blood"},{"issue":"23","key":"10.1002\/14651858.CD014201-BIB0190|cit190","doi-asserted-by":"crossref","first-page":"2300","DOI":"10.1182\/blood.V126.23.2300.2300","article-title":"Joint bleeding patterns in patients treated prophylactically with an extended half-life, pegylated, full-length recombinant factor VIII (BAX 855)","volume":"126","author":"Manco-Johnson","year":"2015","journal-title":"Blood"},{"key":"10.1002\/14651858.CD014201-BIB0191|cit191","first-page":"177","article-title":"Factors influencing the pharmacokinetics of pegylated recombinant factor VIII (BAX 855) administered for prophylaxis in previously treated patients with severe hemophilia A","volume":"13 Suppl 2","author":"Stasyshyn","year":"2015","journal-title":"Journal of Thrombosis and Haemostasis : JTH"},{"issue":"4","key":"10.1002\/14651858.CD014201-BIB0192|cit192","doi-asserted-by":"crossref","first-page":"413","DOI":"10.1046\/j.1365-2516.1998.440413.x","article-title":"When should prophylactic treatment in patients with haemophilia A and B start?- the German experience","volume":"4","author":"Kreuz","year":"1998","journal-title":"Haemophilia"},{"issue":"23","key":"10.1002\/14651858.CD014201-BIB0193|cit193","doi-asserted-by":"crossref","first-page":"1103","DOI":"10.1182\/blood.V126.23.1103.1103","article-title":"Patterns of prior treatment and bleeds among patients with severe hemophilia a: impact on frequency of dosing with bay 81-8973 in the Leopold I trial","volume":"126","author":"Church","year":"2015","journal-title":"Blood"},{"key":"10.1002\/14651858.CD014201-BIB0194|cit194","first-page":"78","article-title":"Bleed occurrence after Bay 81-8973 injection and characteristics of patients who respond to prophylaxis: analyses from Leopold I and II","volume":"22 Suppl 2","author":"Church","year":"2016","journal-title":"Haemophilia"},{"issue":"4","key":"10.1002\/14651858.CD014201-BIB0195|cit195","doi-asserted-by":"crossref","first-page":"528","DOI":"10.1111\/hae.13192","article-title":"Population pharmacokinetic characterization of BAY 81-8973, a full-length recombinant factor VIII: lessons learned - importance of including samples with factor VIII levels below the quantitation limit","volume":"23","author":"Garmann","year":"2017","journal-title":"Haemophilia"},{"issue":"22","key":"10.1002\/14651858.CD014201-BIB0196|cit196","doi-asserted-by":"crossref","first-page":"4984","DOI":"10.1182\/blood.V128.22.4984.4984","article-title":"Rationale for investigator-assigned prophylaxis dosing frequency in the leopold I study","volume":"128","author":"Humphries","year":"2016","journal-title":"Blood"},{"key":"10.1002\/14651858.CD014201-BIB0197|cit197","first-page":"25","article-title":"Study design of 2 randomized, crossover, open-label trials to evaluate the pharmacokinetics, efficacy, and safety of plasma protein-free recombinant factor VIII formulated with sucrose (BAY 81-8973)","volume":"18 Suppl 3","author":"Kavakli","year":"2012","journal-title":"Haemophilia"},{"key":"10.1002\/14651858.CD014201-BIB0198|cit198","first-page":"96","article-title":"Leopold trial results: Correlation of von willebrand factor antigen level with bay 81-8973 pharmacokinetic parameters of patients with severe hemophilia A","volume":"13","author":"Lalezari","year":"2015","journal-title":"Journal of Thrombosis and Haemostasis"},{"key":"10.1002\/14651858.CD014201-BIB0199|cit199","first-page":"858","article-title":"Prophylactic efficacy of twice-weekly vs. 3-times-weekly bay 81-8973 in severe hemophilia A: results of the Leopold I and II clinical trials","volume":"13 Suppl 2","author":"Mahlangu","year":"2015","journal-title":"Journal of Thrombosis and Haemostasis"},{"key":"10.1002\/14651858.CD014201-BIB0200|cit200","first-page":"177","article-title":"BAY 81-8973 prophylaxis efficacy in patients with severe hemophilia A: analyses of annualized bleeding rate outcomes in the LEOPOLD I trial","volume":"13 Suppl 2","author":"Mancuso","year":"2015","journal-title":"Journal of Thrombosis and Haemostasis"},{"issue":"3","key":"10.1002\/14651858.CD014201-BIB0201|cit201","doi-asserted-by":"crossref","first-page":"349","DOI":"10.1111\/hae.12839","article-title":"Safety and efficacy of BAY 81-8973 for surgery in previously treated patients with haemophilia A: results of the LEOPOLD clinical trial programme","volume":"22","author":"Oldenburg","year":"2016","journal-title":"Haemophilia"},{"key":"10.1002\/14651858.CD014201-BIB0202|cit202","first-page":"77","article-title":"History of sucrose-formulated recombinant factor VIII (rFVIII-FS) use and reduction in bleeds following Bay 81-8973 prophylaxis in Leopold I","volume":"22 Suppl 2","author":"Pocoski","year":"2016","journal-title":"Haemophilia"},{"key":"10.1002\/14651858.CD014201-BIB0203|cit203","first-page":"34","article-title":"Pharmacokinetic parameters, prophylaxis frequency and bleed outcomes of severe hemophilia A patients treated with BAY 81-8973","volume":"23 Suppl 3","author":"Sajeev","year":"2017","journal-title":"Haemophilia"},{"key":"10.1002\/14651858.CD014201-BIB0204|cit204","first-page":"31","article-title":"Bay 81-8973 demonstrates comparable efficacy during prophylaxis irrespective of the assay determining potency","volume":"21","author":"Saxena","year":"2015","journal-title":"Haemophilia"},{"issue":"5","key":"10.1002\/14651858.CD014201-BIB0205|cit205","doi-asserted-by":"crossref","first-page":"706","DOI":"10.1111\/hae.12952","article-title":"Efficacy and safety of BAY 81-8973, a full-length recombinant factor VIII: results from the LEOPOLD I trial","volume":"22","author":"Saxena","year":"2016","journal-title":"Haemophilia"},{"key":"10.1002\/14651858.CD014201-BIB0206|cit206","first-page":"1076","article-title":"Bay 81-8973 prophylaxis frequency and long-term bleed outcomes in the leopold i extension study","volume":"130 Suppl 1","author":"Saxena","year":"2017","journal-title":"Blood"},{"issue":"6","key":"10.1002\/14651858.CD014201-BIB0207|cit207","doi-asserted-by":"crossref","first-page":"766","DOI":"10.1111\/hae.12691","article-title":"Pharmacokinetic properties of BAY 81-8973, a full-length recombinant factor VIII","volume":"21","author":"Shah","year":"2015","journal-title":"Haemophilia"},{"key":"10.1002\/14651858.CD014201-BIB0208|cit208","first-page":"48","article-title":"Intra-individual across-study comparison of pharmacokinetics of rFVIII-FS, bay 81-8973 and bay 94-9027 in patients with severe haemophilia A","volume":"26","author":"Solms","year":"2020","journal-title":"Haemophilia"},{"key":"10.1002\/14651858.CD014201-BIB0209|cit209","first-page":"64","article-title":"Prophylaxis with bay 81-8973, a full-length plasma-protein-free recombinant factor viii product: Efficacy results in leopold I by baseline patient characteristics","volume":"21","author":"Windyga","year":"2015","journal-title":"Haemophilia"},{"issue":"4","key":"10.1002\/14651858.CD014201-BIB0210|cit210","doi-asserted-by":"crossref","first-page":"973","DOI":"10.1046\/j.1365-2141.1996.420960.x","article-title":"The impact of prophylactic treatment in children with severe haemophilia","volume":"92","author":"Liesner","year":"1996","journal-title":"British Journal of Haematology"},{"issue":"5","key":"10.1002\/14651858.CD014201-BIB0211|cit211","doi-asserted-by":"crossref","first-page":"395","DOI":"10.1046\/j.1365-2796.1997.130135000.x","article-title":"Haemophilia prophylaxis in young patients - a long-term follow-up","volume":"241","author":"L\u00f6fqvist","year":"1997","journal-title":"Journal of Internal Medicine"},{"issue":"23","key":"10.1002\/14651858.CD014201-BIB0212|cit212","doi-asserted-by":"crossref","first-page":"1105","DOI":"10.1182\/blood.V126.23.1105.1105","article-title":"Characteristics of patients without bleeding in a pivotal trial of extended half-life, pegylated, full-length recombinant factor VIII (BAX 855) in the treatment of hemophilia a","volume":"126","author":"Ma","year":"2015","journal-title":"Blood"},{"issue":"2","key":"10.1002\/14651858.CD014201-BIB0213|cit213","doi-asserted-by":"crossref","first-page":"113","DOI":"10.1002\/ajh.2830470209","article-title":"Results of secondary prophylaxis in children with severe hemophilia","volume":"47","author":"Manco-Johnson","year":"1994","journal-title":"American Journal of Hematology"},{"issue":"7","key":"10.1002\/14651858.CD014201-BIB0214|cit214","doi-asserted-by":"crossref","first-page":"458","DOI":"10.1097\/MPH.0b013e318068b1d6","article-title":"Central venous access device infections in children with hemophilia: a comparison of prophylaxis and episodic therapy","volume":"29","author":"Hacker","year":"2007","journal-title":"Journal of Pediatric Hematology\/oncology"},{"key":"10.1002\/14651858.CD014201-BIB0215|cit215","doi-asserted-by":"crossref","unstructured":"Manco-Johnson MJ Abshire TC Brown D Buchanan GR Cohen AR DiMichele D Initial results of a randomized, prospective trial of prophylaxis to prevent joint disease in young children with factor VIII (FVIII) deficiency Blood 2005 106 Suppl","DOI":"10.1182\/blood.V106.11.3.3"},{"issue":"6","key":"10.1002\/14651858.CD014201-BIB0216|cit216","doi-asserted-by":"crossref","first-page":"535","DOI":"10.1056\/NEJMoa067659","article-title":"Prophylaxis versus episodic treatment to prevent joint disease in boys with severe hemophilia","volume":"357","author":"Manco-Johnson","year":"2007","journal-title":"New England Journal of Medicine"},{"key":"10.1002\/14651858.CD014201-BIB0217|cit217","doi-asserted-by":"crossref","first-page":"44","DOI":"10.1046\/j.1365-2516.9.s1.15.x","article-title":"North American prophylaxis studies for persons with severe haemophilia: background, rationale and design","volume":"9\u00a0Suppl 1","author":"Manco-Johnson","year":"2003","journal-title":"Haemophilia"},{"key":"10.1002\/14651858.CD014201-BIB0218|cit218","first-page":"99","article-title":"What is the cost of delaying prophylaxis until the school years? Results from the joint outcome study continuation project","volume":"20","author":"Manco-Johnson","year":"2014","journal-title":"Haemophilia"},{"issue":"21","key":"10.1002\/14651858.CD014201-BIB0219|cit219","doi-asserted-by":"crossref","first-page":"210","DOI":"10.1182\/blood.V122.21.210.210","article-title":"Long-term orthopedic effects of delaying prophylaxis in severe hemophilia a until age 6 years: Results of the Joint Outcome Study Continuation (JOSc)","volume":"122","author":"Manco-Johnson","year":"2013","journal-title":"Blood"},{"issue":"3","key":"10.1002\/14651858.CD014201-BIB0220|cit220","first-page":"179","article-title":"Optimal therapy for severe factor VIII deficiency: study design considerations for a U.S. prospective, randomized controlled trial","volume":"4","author":"Manco-Johnson","year":"1998","journal-title":"Haemophilia"},{"key":"10.1002\/14651858.CD014201-BIB0221|cit221","unstructured":"Joint outcome study clinicaltrials.gov\/show\/NCT00207597"},{"key":"10.1002\/14651858.CD014201-BIB0222|cit222","doi-asserted-by":"crossref","unstructured":"Warren BB Jacobsen L Villalobos-Menuey E Abshire TC Shapiro AD Recht M Non-factor VIII coagulation proteins fail to predict joint outcome in severe hemophilia A Blood 2015 126 23 2289","DOI":"10.1182\/blood.V126.23.2289.2289"},{"key":"10.1002\/14651858.CD014201-BIB0223|cit223","unstructured":"Efficacy, safety, and pharmacokinetic study of prophylactic emicizumab versus no prophylaxis in hemophilia a participants clinicaltrials.gov\/show\/NCT03315455"},{"issue":"Suppl 1","key":"10.1002\/14651858.CD014201-BIB0224|cit224","first-page":"480","article-title":"A randomized, multicenter, open-label, phase III clinical trial to evaluate the efficacy, safety, and pharmacokinetics of prophylactic emicizumab versus no prophylaxis in persons with hemophilia A in the Asia-pacific region (HAVEN 5)","volume":"4","author":"Wang","year":"2020","journal-title":"Research and Practice in Thrombosis and Haemostasis"},{"key":"10.1002\/14651858.CD014201-BIB0225|cit225","unstructured":"The hemophilia inhibitor prevention trial clinicaltrials.gov\/show\/NCT04303559"},{"key":"10.1002\/14651858.CD014201-BIB0226|cit226","first-page":"02 PO 07","article-title":"Interum analysis of a phase 3, prospective, multicenter study to evaluate the pharmacokinetics, immunogenicity, safety, and efficacy of Immunate solvent detergent (Immunate S\/D) in previously treated patients with severe or moderately severe hemophilia A","volume":"10 Suppl 3","author":"Abbuehl","year":"2004","journal-title":"Haemophilia"},{"issue":"2","key":"10.1002\/14651858.CD014201-BIB0227|cit227","doi-asserted-by":"crossref","first-page":"89","DOI":"10.1159\/000118628","article-title":"Pharmacokinetics, efficacy and safety of IMMUNATE solvent\/detergent (IMMUNATE S\/D) in previously treated patients with severe hemophilia A: results of a prospective, multicenter, open-label phase III study","volume":"119","author":"Nemes","year":"2008","journal-title":"Acta Haematologica"},{"issue":"1","key":"10.1002\/14651858.CD014201-BIB0228|cit228","doi-asserted-by":"crossref","first-page":"9","DOI":"10.1111\/j.1365-2516.2006.01412.x","article-title":"Evaluation of pharmacokinetics, efficacy and safety of Immunate solvent detergent in previously treated patients with severe haemophilia A","volume":"13","author":"Nemes","year":"2007","journal-title":"Haemophilia"},{"key":"10.1002\/14651858.CD014201-BIB0229|cit229","first-page":"111","article-title":"Our experience in Sweden with prophylaxis on haemophilia","volume":"34","author":"Nilsson","year":"1970","journal-title":"Bibliotheca Hematologica"},{"issue":"2","key":"10.1002\/14651858.CD014201-BIB0230|cit230","doi-asserted-by":"crossref","first-page":"129","DOI":"10.1111\/j.1651-2227.1976.tb16525.x","article-title":"Hemophilia prophylaxis in Sweden","volume":"65","author":"Nilsson","year":"1976","journal-title":"Acta Paediatrica Scandinavica"},{"issue":"1","key":"10.1002\/14651858.CD014201-BIB0231|cit231","doi-asserted-by":"crossref","first-page":"25","DOI":"10.1111\/j.1365-2796.1992.tb00546.x","article-title":"Twenty-five years experience of prophylactic treatment in severe haemophilia A and B","volume":"232","author":"Nilsson","year":"1992","journal-title":"Journal of Internal Medicine"},{"key":"10.1002\/14651858.CD014201-BIB0232|cit232","first-page":"151","article-title":"The global, multi-center, phase III, randomized, efficacy, pharmacokinetic and safety cross-over study (PERSEPT 1) of two dose regimens of eptacog beta (rhFVIIa) in congenital hemophilia A and B patients with inhibitors to factor VIII or IX (HABI)","volume":"22 Suppl 4","author":"Wang","year":"2016","journal-title":"Haemophilia"},{"issue":"6","key":"10.1002\/14651858.CD014201-BIB0233|cit233","doi-asserted-by":"crossref","first-page":"832","DOI":"10.1111\/hae.13301","article-title":"PERSEPT 1: a phase 3 trial of activated eptacog beta for on-demand treatment of haemophilia inhibitor-related bleeding","volume":"23","author":"Wang","year":"2017","journal-title":"Haemophilia"},{"issue":"3","key":"10.1002\/14651858.CD014201-BIB0234|cit234","doi-asserted-by":"crossref","first-page":"280","DOI":"10.1097\/00043426-199123000-00006","article-title":"Prophylaxis with factor concentrates in preventing hemophilic arthropathy","volume":"13","author":"Petrini","year":"1991","journal-title":"American Journal of Pediatric Hematology\/Oncology"},{"issue":"4","key":"10.1002\/14651858.CD014201-BIB0235|cit235","doi-asserted-by":"crossref","first-page":"565","DOI":"10.1111\/j.1651-2227.1981.tb05741.x","article-title":"Radiologic evaluation of prophylaxis in severe haemophilia","volume":"70","author":"Pettersson","year":"1981","journal-title":"Acta Paediatric of Scandinavia"},{"key":"10.1002\/14651858.CD014201-BIB0236|cit236","unstructured":"Fusco F Gringeri A Leissinger C Cortesi PA Mantovani LG Bleeding prophylaxis with an anti-inhibitor coagulant complex (AICC) in patients with hemophilia A and inhibitors can improve quality of life: results of the PRO-FEIBA Study 16th Congress of the European Hematology Association; 2011 June 9-12; London, UK 2011"},{"key":"10.1002\/14651858.CD014201-BIB0237|cit237","first-page":"927","article-title":"Bleeding prophylaxis with an anti-inhibitor coagulant complex (AICC) in patients with hemophilia a and inhibitors can improve quality of life: results of the pro-FEIBA study","volume":"9 Suppl 2","author":"Gringeri","year":"2011","journal-title":"Journal of Thrombosis and Haemostasis"},{"issue":"5","key":"10.1002\/14651858.CD014201-BIB0238|cit238","doi-asserted-by":"crossref","first-page":"736","DOI":"10.1111\/hae.12178","article-title":"Health-related quality of life in patients with haemophilia and inhibitors on prophylaxis with anti-inhibitor complex concentrate: results from the Pro-FEIBA study","volume":"19","author":"Gringeri","year":"2013","journal-title":"Haemophilia"},{"key":"10.1002\/14651858.CD014201-BIB0239|cit239","doi-asserted-by":"crossref","unstructured":"Gringeri A Leissinger CA Cortesi P Jo H Mantovani L Cost-effectiveness of prophylaxis with anti-inhibitor complex concentrate in patients with hemophilia A and inhibitors: results from the Pro-FEIBA study Blood 2011 118 21","DOI":"10.1182\/blood.V118.21.4187.4187"},{"key":"10.1002\/14651858.CD014201-BIB0240|cit240","first-page":"70","article-title":"Pharmacoeconomic evaluation with an activated prothrombin complex concentrate (APCC) in patients with hemophilia and inhibitors (PRO-FEIBA Study)","volume":"18 Suppl 3","author":"Gringeri","year":"2012","journal-title":"Haemophilia"},{"issue":"7","key":"10.1002\/14651858.CD014201-BIB0241|cit241","doi-asserted-by":"crossref","first-page":"A418","DOI":"10.1016\/j.jval.2011.08.1019","article-title":"Evaluating the cross-over effect on health-related quality of life in a randomized cross-over study of hemophilia-a patients","volume":"14","author":"Jo","year":"2011","journal-title":"Value in Health"},{"issue":"18","key":"10.1002\/14651858.CD014201-BIB0242|cit242","doi-asserted-by":"crossref","first-page":"1684","DOI":"10.1056\/NEJMoa1104435","article-title":"Anti-inhibitor coagulant complex prophylaxis in hemophilia with inhibitors","volume":"365","author":"Leissinger","year":"2011","journal-title":"New EnglandJournal of Medicine"},{"key":"10.1002\/14651858.CD014201-BIB0243|cit243","first-page":"31","article-title":"A prospective, randomized, and crossover study of an activated prothrombin complex concentrate for secondary prophylaxis in patients with hemophilia A and inhibitors (Pro-FEIBA): subject demographics and safety data","volume":"16 Suppl 4","author":"Leissinger","year":"2010","journal-title":"Haemophilia"},{"issue":"21","key":"10.1002\/14651858.CD014201-BIB0244|cit244","doi-asserted-by":"crossref","first-page":"720","DOI":"10.1182\/blood.V116.21.720.720","article-title":"Prophylactic dosing of anti-inhibitor coagulant complex (FEIBA) reduces bleeding frequency in hemophilia a patients with inhibitors: results of the pro-FEIBA study","volume":"116","author":"Leissinger","year":"2010","journal-title":"Blood"},{"issue":"21","key":"10.1002\/14651858.CD014201-BIB0245|cit245","doi-asserted-by":"crossref","first-page":"720","DOI":"10.1182\/blood.V116.21.720.720","article-title":"Prophylactic dosing of anti-inhibitor coagulant complex (FEIBA) reduces bleeding frequency in hemophilia a patients with inhibitors: Results of the pro-FEIBA study","volume":"116","author":"Leissinger","year":"2010","journal-title":"Blood"},{"key":"10.1002\/14651858.CD014201-BIB0246|cit246","doi-asserted-by":"crossref","unstructured":"Leissinger CA Gringeri A Valentino LA Cortesi PA Joint disease and the potential for improved joint health in inhibitor patients who have a good response to aPCC prophylaxis: data from the profeiba study Blood 2012 120 21","DOI":"10.1182\/blood.V120.21.3374.3374"},{"key":"10.1002\/14651858.CD014201-BIB0247|cit247","first-page":"179","article-title":"Health-related quality of life (HRQOL) in bleeding prophylaxis with an activated prothrombin complex concentrate (APCC): results from the Pro-FEIBA study","volume":"18 Suppl 3","author":"Riva","year":"2012","journal-title":"Haemophilia"},{"key":"10.1002\/14651858.CD014201-BIB0248|cit248","first-page":"28","article-title":"Quality of life in pro-FEIBA study","volume":"18 Suppl 1","author":"Riva","year":"2012","journal-title":"Haemophilia"},{"key":"10.1002\/14651858.CD014201-BIB0249|cit249","first-page":"65","article-title":"Bleeding protection using phenotype-guided bay 94-9027 prophylaxis: Protect VIII study subanalyses","volume":"21 Suppl 2","author":"Boggio","year":"2015","journal-title":"Haemophilia"},{"key":"10.1002\/14651858.CD014201-BIB0250|cit250","first-page":"101","article-title":"Consistent control of bleeds among patients with haemophilia A aged >40 years treated with prophylactic bay 94-9027 in the protect VIII study and its extension","volume":"26","author":"Ducore","year":"2020","journal-title":"Haemophilia"},{"key":"10.1002\/14651858.CD014201-BIB0251|cit251","doi-asserted-by":"crossref","unstructured":"Ducore JM Lalezari S Santagostino E Ahuja SP Enriquez MM Tueckmantel C Improvement in quality of life outcomes and bleeding rates among patients switching from on-demand FVIII to prophylactic bay 94-9027 in the protect VIII study Blood 2019 134","DOI":"10.1182\/blood-2019-123947"},{"key":"10.1002\/14651858.CD014201-BIB0252|cit252","unstructured":"A clinical trial investigating safety and efficacy of a long-acting factor VIII in severe hemophila A www.who.int\/trialsearch\/Trial2.aspx?TrialID=EUCTR2011-005210-11-AT"},{"key":"10.1002\/14651858.CD014201-BIB0253|cit253","unstructured":"A clinical trial investigating safety and efficacy of a long-acting factor VIII in severe hemophila A www.who.int\/trialsearch\/Trial2.aspx?TrialID=EUCTR2011-005210-11-Outside-EU\/EEA"},{"key":"10.1002\/14651858.CD014201-BIB0254|cit254","unstructured":"A clinical trial investigating safety and efficacy of a long-acting factor VIII in severe hemophila A www.who.int\/trialsearch\/Trial2.aspx?TrialID=EUCTR2011-005210-11-Outside-EU\/EEA"},{"key":"10.1002\/14651858.CD014201-BIB0255|cit255","first-page":"29","article-title":"Clinical development program for bay 94-9027, a long acting pegylated b-domain-deleted recombinant factor VIII for patients with hemophilia A","volume":"19 Suppl 2","author":"Goerisch","year":"2013","journal-title":"Haemophilia"},{"issue":"Suppl 1","key":"10.1002\/14651858.CD014201-BIB0256|cit256","first-page":"450","article-title":"Efficacy and safety of bay 94-9027 prophylaxis for \u2265 5 years: outcomes in 36 patients from the protect VIII extension study","volume":"4","author":"Holme","year":"2020","journal-title":"Research and Practice in Thrombosis and Haemostasis"},{"key":"10.1002\/14651858.CD014201-BIB0257|cit257","first-page":"151","article-title":"Overall annualised bleeding rates <2 in patients with haemophilia A treated with every-5-day or every-7-day BAY 94-9027 prophylaxis for \u2265100 exposure days","volume":"25","author":"Holme","year":"2019","journal-title":"Haemophilia"},{"key":"10.1002\/14651858.CD014201-BIB0258|cit258","first-page":"786","article-title":"Predictors of patients with 0 bleeds during every-7-days prophylaxis with bay 94-9027 in protect VIII","volume":"1 Suppl 1","author":"Holme","year":"2017","journal-title":"Research and Practice in Thrombosis and Haemostasis"},{"key":"10.1002\/14651858.CD014201-BIB0259|cit259","first-page":"s489","article-title":"Bleeding phenotype and target joints predict patients with zero bleeds given once-weekly prophylaxis with bay 94-9027","volume":"15 Suppl 3","author":"Holme","year":"2017","journal-title":"Blood Transfusion"},{"key":"10.1002\/14651858.CD014201-BIB0260|cit260","first-page":"S17","article-title":"Baseline characteristics and bleeding outcomes in patients with severe hemophilia a administered bay 94-9027 prophylaxis every 5 or every 7 days","volume":"64","author":"Kerlin","year":"2017","journal-title":"Pediatric Blood & Cancer"},{"key":"10.1002\/14651858.CD014201-BIB0261|cit261","first-page":"42","article-title":"Bleeding outcomes during the last 90 days of treatment with BAY 94-9027: results from a post-hoc analysis of the PROTECT VIII study","volume":"25","author":"Liu","year":"2019","journal-title":"Haemophilia"},{"key":"10.1002\/14651858.CD014201-BIB0262|cit262","doi-asserted-by":"crossref","unstructured":"Miesbach WA Di Minno G Santagostino E Klamroth DR Bayh I Soto A Efficacy and safety of bay 94-9027 (damoctocog alfa pegol) prophylaxis in patients with severe hemophilia A and comorbidities: a post hoc analysis of protect VIII data Blood 2019 134 Suppl 1 1117","DOI":"10.1182\/blood-2019-128486"},{"key":"10.1002\/14651858.CD014201-BIB0263|cit263","unstructured":"A trial investigating safety and efficacy of treatment with BAY94-9027 in severe hemophilia a clinicaltrials.gov\/show\/NCT01580293"},{"key":"10.1002\/14651858.CD014201-BIB0264|cit264","first-page":"100","article-title":"Protect VIII: effective protection with BAY 94-9027 prophylaxis given twice weekly, every 5 days, or every 7 days","volume":"23 Suppl 2","author":"Negrier","year":"2017","journal-title":"Haemophilia"},{"key":"10.1002\/14651858.CD014201-BIB0265|cit265","first-page":"114","article-title":"Annualised bleeding rates \u22642 with every-5-day and every-7-day dosing of BAY 94-9027 in the protect VIII study","volume":"25","author":"Oldenburg","year":"2019","journal-title":"Haemophilia"},{"key":"10.1002\/14651858.CD014201-BIB0266|cit266","first-page":"807","article-title":"Protect VIII: can patient characteristics predict eligibility for less frequent prophylaxis dosing regimens?","volume":"1 Suppl 1","author":"Oldenburg","year":"2017","journal-title":"Research and Practice in Thrombosis and Haemostasis"},{"key":"10.1002\/14651858.CD014201-BIB0267|cit267","first-page":"S1","article-title":"Prophylaxis with extended dosing of BAY94-9027 decreases overall and joint bleeding rates with consistent consumption for over 4 years of treatment","volume":"39 Suppl 1","author":"Pabinger","year":"2019","journal-title":"Hamostaseologie"},{"key":"10.1002\/14651858.CD014201-BIB0268|cit268","doi-asserted-by":"crossref","first-page":"2492","DOI":"10.1182\/blood-2018-99-114659","article-title":"Efficacy and safety of Bay 94-9027 is sustained for 5 years: outcomes in 33 patients in the Protect VIII extension study","volume":"132 Suppl 1","author":"Reding","year":"2018","journal-title":"Blood"},{"key":"10.1002\/14651858.CD014201-BIB0269|cit269","first-page":"122","article-title":"Efficacy and safety of BAY 94-9027 is sustained for 5 years: outcomes in 36 patients in the protect VIII extension study","volume":"3","author":"Reding","year":"2019","journal-title":"Research and Practice in Thrombosis and Haemostasis"},{"key":"10.1002\/14651858.CD014201-BIB0270|cit270","first-page":"S276","article-title":"Bay 94-9027 efficacy\/safety sustained for 5 years: data from 33 patients (Protect VIII extension)","volume":"66 Suppl","author":"Reding","year":"2019","journal-title":"Pediatric Blood & Cancer"},{"key":"10.1002\/14651858.CD014201-BIB0271|cit271","first-page":"20","article-title":"Safety and efficacy of prophylaxis and on-demand treatment with BAY 94-9027: results of a phase 2\/3 multicentre, partially randomized, open-label trial","volume":"20 Suppl 3","author":"Reding","year":"2014","journal-title":"Haemophilia"},{"key":"10.1002\/14651858.CD014201-BIB0272|cit272","first-page":"59","article-title":"Characteristics of patients successfully treated on every-7-day dosing in the PROTECT VIII extension (BAY 94-9027) study","volume":"25","author":"Reding","year":"2019","journal-title":"Haemophilia"},{"key":"10.1002\/14651858.CD014201-BIB0273|cit273","doi-asserted-by":"crossref","first-page":"1206","DOI":"10.1182\/blood-2018-99-116272","article-title":"Decrease in overall and joint bleeding rates with extended-interval dosing: > 4 years of bay 94-9027 prophylaxis in the protect VIII extension","volume":"132 Suppl 1","author":"Reding","year":"2018","journal-title":"Blood"},{"issue":"3","key":"10.1002\/14651858.CD014201-BIB0274|cit274","doi-asserted-by":"crossref","first-page":"411","DOI":"10.1111\/jth.13597","article-title":"Safety and efficacy of BAY 94-9027, a prolonged-half-life factor VIII","volume":"15","author":"Reding","year":"2017","journal-title":"Journal of Thrombosis and Haemostasis"},{"key":"10.1002\/14651858.CD014201-BIB0275|cit275","first-page":"17","article-title":"Safety of long-term prophylaxis with BAY 94-9027: interim results of >5 years of treatment in the PROTECT VIII extension trial","volume":"24 Suppl 5","author":"Reding","year":"2018","journal-title":"Haemophilia"},{"key":"10.1002\/14651858.CD014201-BIB0276|cit276","doi-asserted-by":"crossref","first-page":"2486","DOI":"10.1182\/blood-2018-99-116031","article-title":"Characteristics of bleed-free patients on every-5-day dosing in the protect VIII (BAY 94-9027) study","volume":"132 Suppl 1","author":"Santagostino","year":"2018","journal-title":"Blood"},{"key":"10.1002\/14651858.CD014201-BIB0277|cit277","first-page":"41","article-title":"PROTECT VIII Kids trial results: BAY 94-9027 safety and efficacy in previously treated children with severe hemophilia A","volume":"22 Suppl 4","author":"Santagostino","year":"2016","journal-title":"Haemophilia"},{"issue":"5","key":"10.1002\/14651858.CD014201-BIB0278|cit278","doi-asserted-by":"crossref","first-page":"733","DOI":"10.1111\/hae.13561","article-title":"BAY 94-9027, a PEGylated recombinant factor VIII, exhibits a prolonged half-life and higher area under the curve in patients with severe haemophilia A: comprehensive pharmacokinetic assessment from clinical studies","volume":"24","author":"Shah","year":"2018","journal-title":"Haemophilia"},{"key":"10.1002\/14651858.CD014201-BIB0279|cit279","first-page":"99","article-title":"Pharmacokinetics of BAY 94-9027, a PEGylated B-domain-deleted recombinant factor VIII with an extended half-life, in children, adolescents, and adults with severe hemophilia A","volume":"22","author":"Shah","year":"2016","journal-title":"Haemophilia"},{"key":"10.1002\/14651858.CD014201-BIB0280|cit280","first-page":"45","article-title":"BAY 94-9027 and recombinant factor VIII Fc fusion protein: a head-to-head, randomized, crossover, pharmacokinetic study in patients with severe haemophilia A","volume":"25","author":"Shah","year":"2019","journal-title":"Haemophilia"},{"key":"10.1002\/14651858.CD014201-BIB0281|cit281","doi-asserted-by":"crossref","first-page":"1189","DOI":"10.1182\/blood-2018-99-114619","article-title":"Extended interval prophylaxis with bay 94-9027 for &gt; 4 years leads to median spontaneous annualized bleeding rates &lt; 1 in the Protect VIII extension","volume":"132 Suppl 1","author":"Simpson","year":"2018","journal-title":"Blood"},{"issue":"9","key":"10.1002\/14651858.CD014201-BIB0282|cit282","first-page":"E60","article-title":"Bay 94-9027 prophylaxis improves activity and work productivity: data from the protect VIII study","volume":"93","author":"Simpson","year":"2018","journal-title":"American Journal of Hematology"},{"key":"10.1002\/14651858.CD014201-BIB0283|cit283","doi-asserted-by":"crossref","unstructured":"Solms A Delesen H Maas Enriquez M Kenet G Lalezari S Intra-individual across-study comparison of pharmacokinetics of rFVIII-FS, bay 81-8973 and bay 94-9027 in patients with severe haemophilia A Haemophilia 2020 26 48 9","DOI":"10.1111\/hae.13973"},{"key":"10.1002\/14651858.CD014201-BIB0284|cit284","first-page":"114","article-title":"Effective protection for >5 years with bay 94-9027 prophylaxis: interim results from the protect VIII extension trial","volume":"24 Suppl 1","author":"Thomson","year":"2018","journal-title":"Haemophilia"},{"issue":"6","key":"10.1002\/14651858.CD014201-BIB0285|cit285","doi-asserted-by":"crossref","first-page":"611","DOI":"10.1007\/s40271-019-00374-x","article-title":"Exploring the impact of infusion frequency in hemophilia A: exit interviews with patients participating in BAY 94-9027 extension studies (PROTECT VIII)","volume":"12","author":"Wells","year":"2019","journal-title":"Patient"},{"issue":"1","key":"10.1002\/14651858.CD014201-BIB0286|cit286","doi-asserted-by":"crossref","first-page":"e43","DOI":"10.1111\/hae.13131","article-title":"Pilot randomized, non-inferiority, cross-over trial of once-weekly vs. three times-weekly recombinant factor VIII prophylaxis in adults with severe haemophilia A","volume":"23","author":"Ragni","year":"2017","journal-title":"Haemophilia"},{"issue":"5","key":"10.1002\/14651858.CD014201-BIB0287|cit287","doi-asserted-by":"crossref","first-page":"495","DOI":"10.1586\/ehm.11.52","article-title":"Rationale for a randomized controlled trial comparing two prophylaxis regimens in adults with severe hemophilia A: the Hemophilia Adult Prophylaxis Trial","volume":"4","author":"Ragni","year":"2011","journal-title":"Expert Review of Hematology"},{"issue":"4","key":"10.1002\/14651858.CD014201-BIB0288|cit288","doi-asserted-by":"crossref","first-page":"243","DOI":"10.1136\/jcp.26.4.243","article-title":"A trial of prophylactic replacement therapy in haemophilia and Christmas disease","volume":"26","author":"Ramsay","year":"1973","journal-title":"Journal of Clinical Pathology"},{"issue":"1","key":"10.1002\/14651858.CD014201-BIB0289|cit289","doi-asserted-by":"crossref","first-page":"44","DOI":"10.1046\/j.1365-2516.2002.00581.x","article-title":"Quality-of-life differences between prophylactic and on-demand factor replacement therapy in European haemophilia patients","volume":"8","author":"Royal","year":"2002","journal-title":"Haemophilia"},{"issue":"14","key":"10.1002\/14651858.CD014201-BIB0290|cit290","doi-asserted-by":"crossref","first-page":"1761","DOI":"10.1182\/blood-2015-09-669234","article-title":"Long-acting recombinant coagulation factor IX albumin fusion protein (rIX-FP) in hemophilia B: results of a phase 3 trial","volume":"127","author":"Santagostino","year":"2016","journal-title":"Blood"},{"key":"10.1002\/14651858.CD014201-BIB0291|cit291","first-page":"1979","article-title":"Hemophilia A prophylaxis with factor VIII concentrate in a home-treatment program: a controlled study","volume":"30","author":"Schimpf","year":"1977","journal-title":"Scandinavian Journal of Haematology. Supplementum"},{"issue":"1","key":"10.1002\/14651858.CD014201-BIB0292|cit292","doi-asserted-by":"crossref","first-page":"71","DOI":"10.1160\/TH07-06-0417","article-title":"Effect of primary and secondary prophylaxis on the clinical expression of joint damage in children with severe haemophilia A","volume":"99","author":"Schobess","year":"2008","journal-title":"Thrombosis and Haemostasis"},{"key":"10.1002\/14651858.CD014201-BIB0293|cit293","unstructured":"BAY94-9027 PK Study Comparing to Another Long Acting Product clinicaltrials.gov\/show\/NCT03364998 2017"},{"issue":"9","key":"10.1002\/14651858.CD014201-BIB0294|cit294","doi-asserted-by":"crossref","first-page":"2035","DOI":"10.1007\/s00277-019-03747-2","article-title":"Direct comparison of two extended-half-life recombinant FVIII products: a randomized, crossover pharmacokinetic study in patients with severe hemophilia A","volume":"98","author":"Shah","year":"2019","journal-title":"Annals of Hematology"},{"key":"10.1002\/14651858.CD014201-BIB0295|cit295","first-page":"74","article-title":"Intra-individual across-study comparison of the pharmacokinetics of four recombinant factor VIII products in patients with severe haemophilia A","volume":"26 Suppl 2","author":"Solms","year":"2020","journal-title":"Haemophilia"},{"issue":"Suppl 2","key":"10.1002\/14651858.CD014201-BIB0296|cit296","first-page":"1","article-title":"Subcutaneous prophylaxis with the anti-TFPI monoclonal antibody concizumab in hemophilia A and hemophilia A\/B with inhibitors: phase 2 trial results","volume":"3","author":"Astermark","year":"2019","journal-title":"Research and practice in thrombosis and haemostasis"},{"key":"10.1002\/14651858.CD014201-BIB0297|cit297","unstructured":"A trial evaluating the efficacy and safety of prophylactic administration of concizumab in haemophilia a and b patients with inhibitors www.who.int\/trialsearch\/Trial2.aspx?TrialID=EUCTR2016-000510-30-ES"},{"key":"10.1002\/14651858.CD014201-BIB0298|cit298","doi-asserted-by":"crossref","first-page":"2419","DOI":"10.1182\/blood-2019-122827","article-title":"Concizumab subcutaneous prophylaxis improves health-related quality-of-life measures in patients with congenital hemophilia with inhibitors: phase 2 trial results","volume":"134 Suppl 1","author":"Lee","year":"2019","journal-title":"Blood"},{"key":"10.1002\/14651858.CD014201-BIB0299|cit299","unstructured":"A trial evaluating the efficacy and safety of prophylactic administration of concizumab in haemophilia a and b patients with inhibitors (explorer\u21224) clinicaltrials.gov\/show\/NCT03196284"},{"key":"10.1002\/14651858.CD014201-BIB0300|cit300","doi-asserted-by":"crossref","first-page":"1139","DOI":"10.1182\/blood-2019-122809","article-title":"Efficacy and safety of subcutaneous prophylaxis with concizumab in patients with hemophilia A or B with inhibitors: results from explorer4, a phase 2, randomized, open-label, controlled trial","volume":"134 Suppl 1","author":"Shapiro","year":"2019","journal-title":"Blood"},{"issue":"22","key":"10.1002\/14651858.CD014201-BIB0301|cit301","doi-asserted-by":"crossref","first-page":"1973","DOI":"10.1182\/blood.2019001542","article-title":"Subcutaneous concizumab prophylaxis in hemophilia A and hemophilia A\/B with inhibitors: phase 2 trial results","volume":"134","author":"Shapiro","year":"2019","journal-title":"Blood"},{"issue":"3","key":"10.1002\/14651858.CD014201-BIB0302|cit302","doi-asserted-by":"crossref","first-page":"424","DOI":"10.1016\/S0022-3476(96)70076-8","article-title":"Episodic versus prophylactic infusions for hemophilia A: a cost-effectiveness analysis","volume":"129","author":"Smith","year":"1996","journal-title":"Journal of Pediatrics"},{"key":"10.1002\/14651858.CD014201-BIB0303|cit303","doi-asserted-by":"crossref","first-page":"1205","DOI":"10.1182\/blood-2018-99-111891","article-title":"Impact of treatment regimen with moroctocog alfa (AF-CC) on bleeding frequency in pediatric aged subjects with moderately severe to severe hemophilia a","volume":"132 Suppl 1","author":"Smith","year":"2018","journal-title":"Blood"},{"issue":"11","key":"10.1002\/14651858.CD014201-BIB0304|cit304","doi-asserted-by":"crossref","first-page":"2689","DOI":"10.1007\/s00277-020-04280-3","article-title":"Direct comparison of two extended half-life PEGylated recombinant FVIII products: a randomized, crossover pharmacokinetic study in patients with severe hemophilia A","volume":"99","author":"Solms","year":"2020","journal-title":"Annals of Hematology"},{"key":"10.1002\/14651858.CD014201-BIB0305|cit305","first-page":"S164","article-title":"Access to prophylaxis benefits hemophilia a subjects in both low and high IU\/capita countries: adult subset analysis of a multicenter, open-label, randomized, phase 4 clinical study of rAHF-PFM","volume":"87 Suppl","author":"Quon","year":"2012","journal-title":"American Journal of Hematology"},{"key":"10.1002\/14651858.CD014201-BIB0306|cit306","first-page":"19","article-title":"Access to prophylaxis benefits hemophilia A subjects in both low and high IU\/capita countries: adult subset analysis of a multi-center, open-label, randomized, phase 4 clinical study of rAHF-PFM","volume":"18 Suppl 1","author":"Song","year":"2012","journal-title":"Haemophilia"},{"issue":"4","key":"10.1002\/14651858.CD014201-BIB0307|cit307","doi-asserted-by":"crossref","first-page":"211","DOI":"10.1111\/j.1365-2516.1996.tb00139.x","article-title":"Socioeconomic impact of haemophilia care: results of a pilot study","volume":"2","author":"Szucs","year":"1996","journal-title":"Haemophilia"},{"issue":"5","key":"10.1002\/14651858.CD014201-BIB0308|cit308","doi-asserted-by":"crossref","first-page":"945","DOI":"10.1111\/j.1365-2516.2008.01791.x","article-title":"Effect of secondary prophylaxis started in adult and haemophiliacs","volume":"14","author":"Tagliaferri","year":"2008","journal-title":"Haemophilia"},{"issue":"3","key":"10.1002\/14651858.CD014201-BIB0309|cit309","doi-asserted-by":"crossref","first-page":"561","DOI":"10.1046\/j.1365-2141.2001.02580.x","article-title":"Long-term outcome of individualized prophylactic treatment of children with severe haemophilia","volume":"112","author":"Van den Berg","year":"2001","journal-title":"British Journal of Haematology"},{"issue":"3","key":"10.1002\/14651858.CD014201-BIB0310|cit310","doi-asserted-by":"crossref","first-page":"342","DOI":"10.1111\/hae.12838","article-title":"A randomized study of very low-dose factor VIII prophylaxis in severe haemophilia - a success story from a resource limited country","volume":"22","author":"Verma","year":"2016","journal-title":"Haemophilia"},{"issue":"3","key":"10.1002\/14651858.CD014201-BIB0311|cit311","doi-asserted-by":"crossref","first-page":"342","DOI":"10.1111\/hae.12838","article-title":"A randomized study of very low-dose factor VIII prophylaxis in severe haemophilia - A success story from a resource limited country","volume":"22","author":"Verma","year":"2016","journal-title":"Haemophilia"},{"issue":"4","key":"10.1002\/14651858.CD014201-BIB0312|cit312","first-page":"345","article-title":"Low dose factor VIII prophylaxis in children with severe hemophilia","volume":"29","author":"Verma","year":"2013","journal-title":"Indian Journal of Hematology & Blood Transfusion"},{"issue":"5","key":"10.1002\/14651858.CD014201-BIB0313|cit313","doi-asserted-by":"crossref","first-page":"674","DOI":"10.1111\/hae.12444","article-title":"Safe switching from a pdFIX (Immunine\u00ae) to a rFIX (Bax326)","volume":"20","author":"Solano Trujillo","year":"2014","journal-title":"Haemophilia"},{"issue":"3","key":"10.1002\/14651858.CD014201-BIB0314|cit314","doi-asserted-by":"crossref","first-page":"362","DOI":"10.1111\/hae.12315","article-title":"Improvement in health-related quality of life with recombinant factor IX prophylaxis in severe or moderately severe haemophilia B patients: results from the BAX326 Pivotal Study","volume":"20","author":"Windyga","year":"2014","journal-title":"Haemophilia"},{"issue":"5","key":"10.1002\/14651858.CD014201-BIB0315|cit315","doi-asserted-by":"crossref","first-page":"651","DOI":"10.1111\/hae.12419","article-title":"Efficacy and safety of a recombinant factor IX (Bax326) in previously treated patients with severe or moderately severe haemophilia B undergoing surgical or other invasive procedures: a prospective, open-label, uncontrolled, multicentre, phase III study","volume":"20","author":"Windyga","year":"2014","journal-title":"Haemophilia"},{"key":"10.1002\/14651858.CD014201-BIB0316|cit316","doi-asserted-by":"crossref","unstructured":"Windyga J Lissitchkov T Stasyshyn O Mamonov V Rusen L Lamas JL Pharmacokinetics, efficacy and safety of BAX326, a novel recombinant factor IX: a prospective, controlled, multicenter study in previously treated patients with severe (FIX level <1%) or moderately severe (FIX level \u22642%) hemophilia B Blood 2012 120 21","DOI":"10.1182\/blood.V120.21.2222.2222"},{"issue":"1","key":"10.1002\/14651858.CD014201-BIB0317|cit317","doi-asserted-by":"crossref","first-page":"15","DOI":"10.1111\/hae.12228","article-title":"Pharmacokinetics, efficacy and safety of BAX326, a novel recombinant factor IX: a prospective, controlled, multicentre phase I\/III study in previously treated patients with severe (FIX level &lt;1%) or moderately severe (FIX level \u22642%) haemophilia B","volume":"20","author":"Windyga","year":"2014","journal-title":"Haemophilia"},{"issue":"1","key":"10.1002\/14651858.CD014201-BIB0318|cit318","doi-asserted-by":"crossref","first-page":"15","DOI":"10.1111\/hae.12228","article-title":"Pharmacokinetics, efficacy and safety of BAX326, a novel recombinant factor IX: A prospective, controlled, multicentre phase I\/III study in previously treated patients with severe (FIX level <1%) or moderately severe (FIX level <2%) haemophilia B","volume":"20","author":"Windyga","year":"2013","journal-title":"Haemophilia"},{"issue":"1","key":"10.1002\/14651858.CD014201-BIB0319|cit319","doi-asserted-by":"crossref","first-page":"70","DOI":"10.1111\/j.1365-2516.2010.02348.x","article-title":"Low dose secondary prophylaxis reduces joint and severe bleeding in severe and moderate hemophilia children: A pilot study in China","volume":"17","author":"Wu","year":"2011","journal-title":"Haemophilia"},{"issue":"6","key":"10.1002\/14651858.CD014201-BIB0320|cit320","doi-asserted-by":"crossref","first-page":"967","DOI":"10.1111\/jth.12911","article-title":"Recombinant factor VIII Fc fusion protein for the prevention and treatment of bleeding in children with severe hemophilia A","volume":"13","author":"Young","year":"2015","journal-title":"Journal of Thrombosis and Haemostasis"},{"key":"10.1002\/14651858.CD014201-BIB0321|cit321","first-page":"229","article-title":"Improved health-related quality of life (QoL) of haemophilia B patients treated with a weekly 40 IU kg-1 dose of a new long-acting recombinant factor IX (FIX) product, nonacog beta pegol","volume":"13 Suppl 2","author":"Chowdary","year":"2015","journal-title":"Journal of Thrombosis and Haemostasis : JTH"},{"issue":"3","key":"10.1002\/14651858.CD014201-BIB0322|cit322","doi-asserted-by":"crossref","first-page":"A300","DOI":"10.1016\/j.jval.2015.03.1747","article-title":"Improved health status of haemophilia b patients treated with nonacog beta pegol, a new glycopegylated recombinant fix product with prolonged half-life","volume":"18","author":"Chowdary","year":"2015","journal-title":"Value in Health"},{"key":"10.1002\/14651858.CD014201-BIB0323|cit323","first-page":"793","article-title":"Comparison of the relationship between factor IX activity and bleeding risk during prophylaxis with nonacog beta pegol (N9-GP)","volume":"1 Suppl 1","author":"Young","year":"2017","journal-title":"Journal of Thrombosis and Haemostasis"},{"key":"10.1002\/14651858.CD014201-BIB0324|cit324","first-page":"7","article-title":"Haemophilia in Sweden VII. Incidence, treatment and prophylaxis of arthropathy and other musculoskeletal manifestations of haemophilia A and B","volume":"77 Suppl 1","author":"Ahlberg","year":"1965","journal-title":"Acta Orthopedic Scandinavian"},{"key":"10.1002\/14651858.CD014201-BIB0325|cit325","first-page":"1","article-title":"Consensus perspectives in prophylactic therapy for haemophilia: summary statement","volume":"9 Suppl 1","author":"Berntorp","year":"2000","journal-title":"Haemophilia"},{"key":"10.1002\/14651858.CD014201-BIB0326|cit326","doi-asserted-by":"crossref","first-page":"97","DOI":"10.1111\/j.1365-2516.2004.00998.x","article-title":"Optimizing factor prophylaxis for the haemophilia population: where do we stand?","volume":"10 Suppl 4","author":"Blanchette","year":"2004","journal-title":"Haemophilia"},{"issue":"11","key":"10.1002\/14651858.CD014201-BIB0327|cit327","doi-asserted-by":"crossref","first-page":"1935","DOI":"10.1111\/jth.12672","article-title":"Definitions in hemophilia: communication from the SSC of the ISTH","volume":"12","author":"Blanchette","year":"2014","journal-title":"Journal of Thrombosis and Haemostasis"},{"key":"10.1002\/14651858.CD014201-BIB0328|cit328","unstructured":"Deeks JJ Higgins JP Chapter 10: Analysing data and undertaking meta-analyses. In: Higgins JP, Thomas J, Chandler J, Cumpston M, Li T, Page MJ, Welch VA (editors). Cochrane Handbook for Systematic Reviews of Interventions version 6.2\u00a0(updated February\u00a02021). Cochrane, 2021 Available from www.training.cochrane.org\/handbook"},{"issue":"5","key":"10.1002\/14651858.CD014201-BIB0329|cit329","doi-asserted-by":"crossref","first-page":"755","DOI":"10.1111\/hae.13589","article-title":"Value of prophylaxis vs on-demand treatment: application of a value framework in hemophilia","volume":"24","author":"Nugent","year":"2018","journal-title":"Haemophilia"},{"key":"10.1002\/14651858.CD014201-BIB0330|cit330","doi-asserted-by":"crossref","first-page":"10","DOI":"10.1111\/j.1365-2516.2007.01500.x","article-title":"Prophylaxis in adults with haemophilia","volume":"13 Suppl 2","author":"Hay","year":"2007","journal-title":"Haemophilia"},{"key":"10.1002\/14651858.CD014201-BIB0331|cit331","unstructured":"Higgins JP Altman DG Sterne JA on behalf of the Cochrane Statistical Methods Group Chapter 8: Assessing risk of bias in included studies. In: Higgins JP, Green S, editor(s). Cochrane Handbook for Systematic Reviews of Interventions Version 5.2 (updated June 2017). The Cochrane Collaboration, 2017 Available from training.cochrane.org\/handbook\/archive\/v5.2"},{"key":"10.1002\/14651858.CD014201-BIB0332|cit332","unstructured":"Higgins JP Eldridge S Higgins JP, Eldridge S, Li T (editors). Chapter 23: Including variants on randomized trials. In: Higgins JP, Thomas J, Chandler J, Cumpston M, Li T, Page MJ, Welch VA (editors). Cochrane Handbook for Systematic Reviews of Interventions version 6.2\u00a0(updated February\u00a02021). Cochrane, 2021 Available from www.training.cochrane.org\/handbook"},{"key":"10.1002\/14651858.CD014201-BIB0333|cit333","doi-asserted-by":"crossref","first-page":"139","DOI":"10.1016\/S0065-3101(22)00847-7","article-title":"Hemophilic arthropathy","volume":"21","author":"Hilgartner","year":"1974","journal-title":"Advances in Pediatrics"},{"issue":"9","key":"10.1002\/14651858.CD014201-BIB0334|cit334","doi-asserted-by":"publisher","DOI":"10.1002\/14651858.CD003429.pub4","article-title":"Clotting factor concentrates given to prevent bleeding and bleeding-related complications in people with hemophilia A or B","author":"Iorio","year":"2011","journal-title":"Cochrane Database of Systematic Reviews"},{"issue":"8","key":"10.1002\/14651858.CD014201-BIB0335|cit335","doi-asserted-by":"crossref","first-page":"e12","DOI":"10.2106\/JBJS.RVW.16.00100","article-title":"Evidence-based management of the knee in hemophilia","volume":"5","author":"Liddle","year":"2017","journal-title":"JBJS Reviews"},{"issue":"1","key":"10.1002\/14651858.CD014201-BIB0336|cit336","doi-asserted-by":"crossref","first-page":"726","DOI":"10.1055\/s-0038-1657619","article-title":"Prophylaxis in children with hemophilia: is it the optimal treatment?","volume":"78","author":"Lusher","year":"1997","journal-title":"Thrombosis Haemostasis"},{"key":"10.1002\/14651858.CD014201-BIB0337|cit337","unstructured":"National Hemophilia Foundation MASAC MASAC recommendation concerning prophylaxis (regular administration of clotting factor concentrate to prevent bleeding). Document 107 www.hemophilia.org\/NHFWeb\/MainPgs\/MainNHF.aspx?menuid=57&contentid=582"},{"key":"10.1002\/14651858.CD014201-BIB0338|cit338","unstructured":"National Hemophilia Foundation MASAC MASAC Recommendation Concerning Prophylaxis. Document 241 www.hemophilia.org\/healthcare-professionals\/guidelines-on-care\/masac-documents\/masac-document-241-recommendation-concerning-prophylaxis"},{"issue":"1","key":"10.1002\/14651858.CD014201-BIB0339|cit339","first-page":"35","article-title":"Benefits of prophylaxis versus on-demand treatment in adolescents and adults with severe haemophilia A: the POTTER study","volume":"114","author":"Tagliaferri","year":"2015","journal-title":"Thrombosis and Haemostasis"},{"issue":"5","key":"10.1002\/14651858.CD014201-BIB0340|cit340","doi-asserted-by":"crossref","first-page":"684","DOI":"10.1111\/bjh.16704","article-title":"Guidelines on the use of prophylactic factor replacement for children and adults with haemophilia A and B","volume":"190","author":"Rayment","year":"2020","journal-title":"British Journal of Haematology"},{"key":"10.1002\/14651858.CD014201-BIB0341|cit341","unstructured":"Review Manager 5 (RevMan 5) Nordic Cochrane Centre, The Cochrane Collaboration 2014"},{"issue":"4","key":"10.1002\/14651858.CD014201-BIB0342|cit342","doi-asserted-by":"crossref","first-page":"498","DOI":"10.1111\/j.1365-2141.2010.08139.x","article-title":"A United Kingdom Haemophilia Centre Doctors' Organization guideline approved by the British Committee for Standards in Haematology: guideline on the use of prophylactic factor VIII concentrate in children and adults with severe haemophilia A","volume":"149","author":"Richards","year":"2010","journal-title":"British Journal of Haematology"},{"issue":"Suppl 6","key":"10.1002\/14651858.CD014201-BIB0343|cit343","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1111\/hae.14046","article-title":"WFH Guidelines for the Management of Hemophilia, 3rd edition","volume":"26","author":"Srivastava","year":"2020","journal-title":"Haemophilia"},{"key":"10.1002\/14651858.CD014201-BIB0344|cit344","doi-asserted-by":"crossref","first-page":"1677","DOI":"10.2147\/PPA.S139851","article-title":"Treatment adherence in hemophilia","volume":"11","author":"Thornburg","year":"2017","journal-title":"Patient Prefer Adherence"},{"issue":"4","key":"10.1002\/14651858.CD014201-BIB0345|cit345","doi-asserted-by":"crossref","first-page":"604","DOI":"10.1111\/hae.12932","article-title":"Declining trends in invasive orthopedic interventions for people with hemophilia enrolled in the Universal Data Collection program (2000-2010)","volume":"22","author":"Tobase","year":"2016","journal-title":"Haemophilia"},{"issue":"6","key":"10.1002\/14651858.CD014201-BIB0346|cit346","doi-asserted-by":"crossref","first-page":"621","DOI":"10.1177\/1740774516649595","article-title":"Quantifying over-estimation in early stopped clinical trials and the \"freezing effect\" on subsequent research","volume":"13","author":"Wang","year":"2016","journal-title":"Clinical Trials"}],"container-title":["Cochrane Database of Systematic Reviews"],"original-title":[],"language":"en","deposited":{"date-parts":[[2023,11,7]],"date-time":"2023-11-07T09:43:39Z","timestamp":1699350219000},"score":1,"resource":{"primary":{"URL":"http:\/\/doi.wiley.com\/10.1002\/14651858.CD014201"}},"subtitle":[],"editor":[{"name":"Cochrane Cystic Fibrosis and Genetic Disorders Group","sequence":"first","affiliation":[],"role":[{"role":"editor","vocabulary":"crossref"}]}],"short-title":[],"issued":{"date-parts":[[2021,8,18]]},"references-count":346,"journal-issue":{"issue":"8","published-online":{"date-parts":[[2021,8]]}},"URL":"https:\/\/doi.org\/10.1002\/14651858.cd014201","relation":{},"ISSN":["1465-1858"],"issn-type":[{"value":"1465-1858","type":"electronic"}],"subject":[],"published":{"date-parts":[[2021,8,18]]}}}